ClinicalTrials.gg
CompletedNCT04158648HAVEN 6Updated Aug 27, 2026Results posted

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

A Phase 3 interventional study of Emicizumab in Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor and Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 22 sites in 10 countries. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.

Enrollment
7th of 22
73 · median 27
Started
2020
the only one that year
Phase 3
11 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
10 of 22
Hoffmann-La Roche

Among the 22 studies testing emicizumab in Hemophilia A, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 11 in phase 3, and was the 10th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About emicizumab

emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing emicizumab in Hemophilia A, or all of them as a file.
02

Study summary

This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without inhibitors against factor VIII (FVIII).

03

Conditions studied

  • Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor
  • Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
  • Hemophilia A

Browse trials for

Keywords

  • Mild Hemophilia A Without Factor VIII Inhibitors
  • Moderate Hemophilia A Without Factor VIII Inhibitors
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of mild (FVIII level between >5% and \<40%) or moderate (FVIII level between ≥1% and ≤5%) congenital Hemophilia A without FVIII inhibitors
  • Weight ≥3 kilograms (kg)
  • Need for prophylaxis based on investigator assessment
  • A negative test for inhibitor (i.e., \<0.6 Bethesda Units per milliliter [BU/mL]) within 8 weeks prior to enrollment
  • No documented inhibitor (i.e., \<0.6 BU/mL), FVIII half-life \<6 hours, or FVIII recovery \<66% in the last 5 years
  • Documentation of the details of prophylactic or episodic FVIII treatment and of number of bleeding episodes for at least the last 24 weeks prior to enrollment
  • Adequate hematologic, hepatic, and renal function
  • For women of : agreement to remain abstinent or use (as defined in the protocol) during the treatment period and for at least 24 weeks after the final dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than mild or moderate congenital hemophilia A
  • History of illicit drug or alcohol abuse within 48 weeks prior to screening, in the investigator's judgment
  • Previous (within the last 12 months) or current treatment for thromboembolic disease or signs of thromboembolic disease
  • Other conditions that may currently increase the risk of bleeding or thrombosis
  • History of associated with monoclonal antibody therapies or components of the emicizumab injection
  • Planned surgery during the emicizumab loading dose phase (surgeries in participants on emicizumab from Week 5 onwards are allowed)
  • Known infection with \<200 cells per microlitre (/μL)
  • Concomitant disease, condition, significant abnormality on screening evaluation or laboratory tests, or treatment that could interfere with the conduct of the study, or that would in the opinion of the investigator, pose an additional unacceptable risk in administering study drug to the participant
  • Receipt of any of the following: An drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration with the exception of prior emicizumab prophylaxis; A non-hemophilia-related investigational drug within last 30 days or 5 half-lives, whichever is shorter; or Any other investigational drug currently being administered or planned to be administered
  • Inability to comply with the study protocol in the opinion of the investigator
  • Pregnant or breastfeeding, or intending to become pregnant during the study (women of must have a negative serum pregnancy test result within 7 days prior to initiation of study drug)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Emicizumab

    Participants with mild and moderate hemophilia A without factor VIII (FVIII) inhibitors will be enrolled to receive the emicizumab loading dose regimen followed by the participant's preference of one of 3 maintenance dose regimens.

    Drug: Emicizumab

Interventions

  • Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).

    Also known as: Hemlibra, RO5534262, RG6013, ACE910

06

What researchers measure

Primary outcomes

  1. Model-Based Annualized Bleed Rate for Treated Bleeds

    The number of treated bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  2. Mean Calculated ABR for Treated Bleeds

    The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  3. Median Calculated ABR for Treated Bleeds

    The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

Secondary outcomes

  1. Model-Based ABR for All Bleeds

    The number of all bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  2. Mean Calculated ABR for All Bleeds

    The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  3. Median Calculated ABR for All Bleeds

    The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  4. Model-Based ABR for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  5. Mean Calculated ABR for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  6. Median Calculated ABR for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  7. Model-Based ABR for Treated Target Joint Bleeds

    The number of treated target joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  8. Mean Calculated ABR for Treated Target Joint Bleeds

    The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  9. Median Calculated ABR for Treated Target Joint Bleeds

    The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  10. Model-Based ABR for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  11. Mean Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  12. Median Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)

  13. Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Bleeds

    The number of treated bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  14. Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Bleeds

    The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  15. Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Bleeds

    The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  16. Long-term Efficacy of Emicizumab: Model-Based ABR for All Bleeds

    The number of all bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  17. Long-term Efficacy of Emicizumab: Mean Calculated ABR for All Bleeds

    The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  18. Long-term Efficacy: Median Calculated ABR for All Bleeds

    The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  19. Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  20. Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  21. Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Joint Bleeds

    The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  22. Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Target Joint Bleeds

    The number of treated target joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  23. Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Target Joint Bleeds

    The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  24. Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Target Joint Bleeds

    The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  25. Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  26. Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  27. Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Spontaneous Bleeds

    The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

    Time frame: median [range, min-max] efficacy period: 156.07 [24.1-274] weeks

  28. CATCH Questionnaire for Adult Participants: Change From Baseline in the Daily Activity Risk Perception (RP) and Impact Domain Scores Over Time

    Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the daily activity RP and impact domain has 48 items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing daily activities and higher impact of hemophilia on daily activities.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and Study completion (SC)/Early discontinuation (ED) (up to approximately 274 weeks)

  29. CATCH Questionnaire for Adult Participants: Change From Baseline in the Social Activity RP and Impact Domain Scores Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the social activity RP and impact domain has 22 items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing social activities and higher impact of hemophilia on social activities.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)

  30. CATCH Questionnaire for Adult Participants: Change From Baseline in the Recreational Activity RP and Impact Domain Scores Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the recreational activity RP and impact domain has 32 items and a larger bank of additional items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing recreational activities and higher impact of hemophilia on recreational activities.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  31. CATCH Questionnaire for Adult Participants: Change From Baseline in the Work Impact (WI) and College Impact (CI) Domains Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, work and college impact has 10 items and the items were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated impact of hemophilia on work and college activities.

    Time frame: WI: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks); CI: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, and SC/ED (up to approximately 274 weeks)

  32. CATCH Questionnaire for Adult Participants: Change From Baseline in the Preoccupation Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, preoccupation has 10 items which were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)

  33. CATCH Questionnaire for Adult Participants: Change From Baseline in the Treatment Burden Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, treatment burden has 8 items which were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater perceived burden of the hemophilia treatment.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)

  34. CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain Associated With a Bleed Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consisting of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question: "Did you get a bleed in the past 7 days?" If the response was yes, participants were asked to rate their pain by selecting the number that best described the pain associated with the bleed. Data is reported only for categories/timepoints with non-zero values.

    Time frame: Baseline, Weeks 25, 49, 61, 85, 121, 133, 157 and 169 and SC/ED (up to approximately 274 weeks)

  35. CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain in Target Joints Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Do you have target joints?" (If yes, please rate your pain by picking the number that best describes your pain in your target joint(s) over the past 7 days). Data is reported only for categories/timepoints with non-zero values.

    Time frame: Baseline, Weeks 1, 13, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)

  36. CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Worst Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its WORST over the past 7 days". Data is reported only for categories/timepoints with non-zero values.

    Time frame: Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)

  37. CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Least Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its LEAST over the past 7 days." Data is reported only for categories/timepoints with non-zero values.

    Time frame: Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)

  38. CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Least on the Average Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its average over the past 7 days". Data is reported only for categories/timepoints with non-zero values.

    Time frame: Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)

  39. CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Daily Activity RP and Impact Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, daily activity RP and impact has 38 items with each item scored on 3 or 4 points ordinal scale. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicating higher perceived risk of having a bleed while doing daily activities and higher impact of hemophilia on daily activities.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  40. CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Social Activity Risk Perception and Impact Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, social activity RP and impact has 16 items which were scored on 3 or 4 points ordinal scale. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher perceived risk of having a bleed while doing social activities and higher impact of hemophilia on social activities.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  41. CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Recreational Activity RP and Impact Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, recreational activity RP \& impact has 34 items + larger bank of additional items. The items were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher perceived risk of having a bleed while doing recreational activities and higher impact of hemophilia on recreational activities.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  42. CATCH Questionnaire for Pediatric Participants: Change From Baseline in the School Impact Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, school impact has 11 items and the items were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher impact of hemophilia on school activities.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  43. CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Preoccupation Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, preoccupation has 3 items which were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  44. CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Treatment Burden Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, treatment burden has 7 items which were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated lower perceived burden of the hemophilia treatment.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  45. CATCH Questionnaire for Pediatric Participants: Number of Participants by Responses to Their Level of Hurt Associated With a Bleed Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, pain domain (Hurt) consists of two items, assessed using an 11-point numeric rating scale where 0 = no hurt and 10 = a lot of hurt. The data reported here are from participants who answered the following question "Did you get a bleed in the past 7 days? ( If yes, how much did the bleed hurt?)." Data is reported only for categories/timepoints with non-zero values.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 85, 97, 109, 121, 133, 145 and 157

  46. CATCH Questionnaire for Pediatric Participants: Number of Participants by Responses to Their Level of Hurt at Its Worst Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, pain domain (Hurt) consists of two items, assessed using an 11-point numeric rating scale where 0 = no hurt and 10 = a lot of hurt. The data reported here are from participants who answered the following question "What is the WORST that your body has hurt over the past 7 days". Data is reported only for categories/timepoints with non-zero values.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145,157, 169 and SC/ED (up to approximately 274 weeks)

  47. CATCH Questionnaire for Caregivers: Change From Baseline in the Preoccupation Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on caregivers of pediatric participants (aged \<8 years). The caregiver version has 2 domains (preoccupation and treatment burden). Of this, preoccupation has 13 items with each of the items were scored on 4 or 5 ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  48. CATCH Questionnaire for Caregivers: Change From Baseline in the Treatment Burden Domain Score Over Time

    CATCH was used to measure the effect of hemophilia and its treatment on caregivers of pediatric participants (aged \<8 years). The caregiver version has 2 domains (preoccupation and treatment burden). Of this, treatment burden has 8 items which were scored on 4 or 5 ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater perceived burden of the hemophilia treatment.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  49. Percentage of Participants Who Prefer Emicizumab SC Treatment, Their Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Week 17

    The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with subcutaneous (SC) emicizumab, intravenous (IV) factor VIIII (FVIII), or no preference. The 95% confidence intervals were calculated using the Pearson-Clopper method.

    Time frame: Week 17

  50. Percentage of Caregivers Who Prefer Emicizumab SC Treatment, Their Child's Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Week 17

    The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the caregiver's preference for their child's treatment with subcutaneous (SC) emicizumab, intravenous (IV) factor VIIII (FVIII), or no preference. The 95% confidence intervals were calculated using the Pearson-Clopper method.

    Time frame: Week 17

  51. Change From Baseline in Hemophilia Joint Health Scores Over Time

    The HJHS measures joint health of the joints (knees, ankles, and elbows) most commonly affected by bleeding in hemophilia. The HJHS 2.1 provides joint specific total scores which are added to obtain the sum of joints totals and also a global gait score. These two scores are then added to obtain HJHS total score. The minimum score per joint is 0, the maximum score is 20. In addition, Gait is scored on a scale from 0 to 4 based on the number of skills that are not within the normal limits. The total score is the sum of scores across all six joints plus the gait score (range from 0 to 124, with 0 being normal and 124 being the most severe disease). A higher score indicates worse joint health.

    Time frame: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)

  52. Change From Baseline in Mean Daily Peak Activity Duration Over Time

    For physical activity assessment, participants ≥5 years of age were instructed to wear the study accelerometry device on the wrist continuously (24 hours/day) every day for the designated 2-week periods during the study. A participant was considered to be compliant with the physical activity assessments if they wore the study device continuously (≥8 hours/day) every day for at least 8 days of each of the designated 2-week periods during the study. If this compliance criterion was not reached at a specific timepoint the participant was not included in the analysis of the designated 2-week periods where compliance was not reached. Daily measurements were averaged over the 14-days timepoint. Activity count was a measure of the acceleration measured by the device. The daily peak activity duration was defined as the sum of moderate to vigorous activity per day (in minutes).

    Time frame: Baseline (Weeks 1-2) and Weeks 13 (Weeks 12-13 period), 25 (Weeks 24-25 period), 37 (Weeks 36-37 period), and 49 (Weeks 48-49 period)

  53. Change From Baseline in Mean Daily Step Count Over Time

    For physical activity assessment, participants ≥5 years of age were instructed to wear the study accelerometry device on the wrist continuously (24 hours/day) every day for the designated 2-week periods during the study. A participant was considered to be compliant with the physical activity assessments if they wore the study device continuously (≥8 hours/day) every day for at least 8 days of each of the designated 2-week periods during the study. If this compliance criterion was not reached at a specific timepoint the participant was not included in the analysis of the designated 2-week periods where compliance was not reached. Daily measurements were averaged over the 14-days timepoint. Activity count was a measure of the acceleration measured by the device.

    Time frame: Baseline (Weeks 1-2) and Weeks 13 (Weeks 12-13), 25 (Weeks 24-25), 37 (Weeks 36-37), and 49 (Weeks 48-49)

  54. Menstrual Bleed Questionnaire (MBQ) for Female Participants of Childbearing Potential: Change From Baseline in the MBQ Total Score Over Time

    The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The MBQ score ranges from 0 to 75. Higher scores indicate a worse quality of life and more severe symptoms.

    Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and145

  55. MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Heaviness Subscale Score Over Time

    The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for heaviness subscale ranges from 0 to 29. Higher score indicates more heavy bleeding.

    Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 89, 93, 97, 101, 104, 109, 113, 121, 125, 129, 133 and 137 (up to approximately 274 weeks)

  56. MBQ for Female Participants of Childbearing Potential: Change From Baseline in the QoL Subscale Score Over Time

    The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for QoL subscale ranges from 0 to 37. Higher scores indicate a worse QoL.

    Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and 145

  57. MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Irregularity Subscale Score Over Time

    The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for irregularity subscale ranges from 0 to 6. Higher score indicates more irregularity.

    Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and 145

  58. MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Pain Subscale Score Over Time

    The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for pain subscale ranges from 0 to 3. Higher score indicates severe pain.

    Time frame: Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 89, 93, 97, 101, 104, 109, 113, 121, 125, 129, 133 and 137

  59. Menstruation Diary With the Pictorial Blood Assessment Chart (PBAC) for Female Participants of Childbearing Potential: PBAC Scores Over Time

    The Menstruation Diary used a PBAC, which has shown good correlation with menstrual blood loss. The PBAC is a chart that records the occurrence and size of clots, and the number of episodes of heavy bleeding (flooding), as well as depicts the amount of blood loss during a cycle.The PBAC records pad and tampon use (as either light \[1 point\], medium \[5 points\], or heavy \[10 points\] flow), clots (small \[1 point\] or large \[5 points\]), and flooding episodes (1 point each) which can be recorded as many times as necessary any day of the month. The PBAC is scored from 0 (no bleeding) onwards, with a score of \>100 defining abnormal coagulation and heavy menstrual bleeding (corresponds to \>80ml of blood loss per menstrual cycle).

    Time frame: Baseline and monthly (on days of menstruation) until Study Completion (up to approximately 247 weeks)

  60. Number of Participants With at Least One Adverse Event by Severity, According to the World Health Organization (WHO) Toxicity Grading Scale

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. As per WHO toxicity grading, Grade 1= mild, 2= moderate, 3=severe, 4=life threatening.

    Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)

  61. Number of Participants With Adverse Events Leading to Study Drug Discontinuation

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)

  62. Number of Participants With at Least One Thromboembolic Event

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The following signs and symptoms were recognized as potential thromboembolism (i.e., dyspnea, chest pain, leg pain, or swelling; or if in the head, headache, numbness in the face, eye pain or swelling, or vision impairment).

    Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)

  63. Number of Participants With at Least One Event of Thrombotic Microangiopathy

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. TMA is used to describe a group of disorders with clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys, gastrointestinal system, central nervous system, etc.

    Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)

  64. Number of Participants With at Least One Injection-Site Reaction by Severity, According to the WHO Toxicity Grading Scale

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Injection-site reactions are defined as AEs related that occur within 24 hours after study drug administration and are judged to be related to the study drug injection. Local injection-site reactions included erythema, hematoma, rash, discomfort, pain, and pruritus and were mostly of mild and moderate intensity. As per WHO toxicity grading, Grade 1= mild, 2= moderate, 3=severe, 4=life threatening.

    Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)

  65. Number of Participants With at Least One Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Event

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)

  66. Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4

    An abnormal laboratory value was defined as a laboratory test result outside of the normal range for hematology or serum chemistry parameters. The WHO toxicity grading scale, which ranges from Grades 1 to 4 (least severe to most severe, respectively; Grade 0 is within normal range), was used for assessing the severity of laboratory abnormalities and adverse events (WHO 2003). Not every laboratory abnormality qualified as an adverse event; an abnormality was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

    Time frame: Up to approximately 274 weeks

  67. Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs

    The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. All of the adverse events reported here were assessed independently by the investigator as not related to treatment with emicizumab.

    Time frame: Up to approximately 274 weeks

  68. Change From Baseline in Electrocardiogram (ECG) Parameters Over Time: QT, QTcB, QTcF, RR, PR, and QRS Intervals

    Time frame: Baseline, Weeks 5, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, SC/ED (up to approximately 274 weeks)

  69. Change From Baseline in Heart Rate Over Time, as Measured by ECG

    Time frame: Baseline, Weeks 5, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, SC/ED (up to approximately 274 weeks)

  70. Plasma Trough Concentration (Ctrough) of Emicizumab Over Time

    Time frame: Pre-dose at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and 181 (up to approximately 274 weeks)

  71. Number of Participants With Anti-Drug Antibodies Against Emicizumab at Baseline and Post-Baseline

    Participants were considered to be ADA positive if they were ADA negative at baseline but develop an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response). The sum of all visits has been reported here.

    Time frame: Baseline, Weeks 5, 13, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 169, 181 and SC/ED (up to approximately 274 weeks)

  72. Number of Participants Who Develop Anti-FVIII Inhibitors Over Time

    Central laboratory measurement of anti-FVIII inhibitory antibodies (inhibitors) was performed using a Chromogenic Bethesda Assay (CBA). Participants who develop anti-FVIII inhibitors (titer ≥ 0.6 Bethesda units per milliliter \[BU/mL\]) following study drug administration were summarized.

    Time frame: Up to approximately 274 weeks

07

Results

Posted Dec 15, 2022

Participant flow

A total of 73 participants with mild or moderate hemophilia A without inhibitors against Factor VIII (FVIII) took part in the study at 22 investigative sites across 10 countries from 10 February 2020 to 19 December 2025.

Participant flow — Overall Study
MilestoneEmicizumab
Started73
Completed 24 weeks in the study72
Completed 52 weeks in the study69
Treated population72
Completed66
Not completed7
Withdrew: Withdrawal by subject7

Outcome measures

PrimaryModel-Based Annualized Bleed Rate for Treated Bleeds

The number of treated bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Number · Treated bleeds per year
Model-Based Annualized Bleed Rate for Treated Bleeds
Treated bleeds per yearEmicizumab
Model-Based Annualized Bleed Rate for Treated Bleeds0.9 (0.55 to 1.52)
PrimaryMean Calculated ABR for Treated Bleeds

The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Mean · Treated bleeds per year
Mean Calculated ABR for Treated Bleeds
Treated bleeds per yearEmicizumab
Mean Calculated ABR for Treated Bleeds0.9 (0.02 to 5.48)
PrimaryMedian Calculated ABR for Treated Bleeds

The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Median · Treated bleeds per year
Median Calculated ABR for Treated Bleeds
Treated bleeds per yearEmicizumab
Median Calculated ABR for Treated Bleeds0.0 (0.00 to 0.98)
SecondaryModel-Based ABR for All Bleeds

The number of all bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Number · All bleeds per year
Model-Based ABR for All Bleeds
All bleeds per yearEmicizumab
Model-Based ABR for All Bleeds2.3 (1.67 to 3.12)
SecondaryMean Calculated ABR for All Bleeds

The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Mean · All bleeds per year
Mean Calculated ABR for All Bleeds
All bleeds per yearEmicizumab
Mean Calculated ABR for All Bleeds2.3 (0.35 to 7.75)
SecondaryMedian Calculated ABR for All Bleeds

The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Median · All bleeds per year
Median Calculated ABR for All Bleeds
All bleeds per yearEmicizumab
Median Calculated ABR for All Bleeds1.0 (0.00 to 3.11)
SecondaryModel-Based ABR for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Number · Treated joint bleeds per year
Model-Based ABR for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Model-Based ABR for Treated Joint Bleeds0.2 (0.09 to 0.57)
SecondaryMean Calculated ABR for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Mean · Treated joint bleeds per year
Mean Calculated ABR for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Mean Calculated ABR for Treated Joint Bleeds0.2 (0.00 to 4.15)
SecondaryMedian Calculated ABR for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Median · Treated joint bleeds per year
Median Calculated ABR for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Median Calculated ABR for Treated Joint Bleeds0.0 (0.00 to 0.00)
SecondaryModel-Based ABR for Treated Target Joint Bleeds

The number of treated target joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Number · Treated target joint bleeds per year
Model-Based ABR for Treated Target Joint Bleeds
Treated target joint bleeds per yearEmicizumab
Model-Based ABR for Treated Target Joint Bleeds0.1 (0.03 to 0.40)
SecondaryMean Calculated ABR for Treated Target Joint Bleeds

The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Mean · Treated target joint bleeds per year
Mean Calculated ABR for Treated Target Joint Bleeds
Treated target joint bleeds per yearEmicizumab
Mean Calculated ABR for Treated Target Joint Bleeds0.1 (0.00 to 3.92)
SecondaryMedian Calculated ABR for Treated Target Joint Bleeds

The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Median · Treated target joint bleeds per year
Median Calculated ABR for Treated Target Joint Bleeds
Treated target joint bleeds per yearEmicizumab
Median Calculated ABR for Treated Target Joint Bleeds0.0 (0.00 to 0.00)
SecondaryModel-Based ABR for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Number · Treated spontaneous bleeds per year
Model-Based ABR for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Model-Based ABR for Treated Spontaneous Bleeds0.2 (0.11 to 0.33)
SecondaryMean Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Mean · Treated spontaneous bleeds per year
Mean Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Mean Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds0.3 (0.00 to 4.23)
SecondaryMedian Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Reported as:
Median · Treated spontaneous bleeds per year
Median Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Median Calculated Annualized Bleed Rate for Treated Spontaneous Bleeds0.0 (0.00 to 0.00)
SecondaryLong-term Efficacy of Emicizumab: Model-Based ABR for Treated Bleeds

The number of treated bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Number · Treated bleeds per year
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Bleeds
Treated bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Bleeds1.0 (0.70 to 1.35)
SecondaryLong-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Bleeds

The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Mean · Treated bleeds per year
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Bleeds
Treated bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Bleeds1.0 (0.02 to 5.54)
SecondaryLong-term Efficacy of Emicizumab: Median Calculated ABR for Treated Bleeds

The number of treated bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
Median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Median · Treated bleeds per year
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Bleeds
Treated bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Bleeds0.4 (0.00 to 1.58)
SecondaryLong-term Efficacy of Emicizumab: Model-Based ABR for All Bleeds

The number of all bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Number · All bleeds per year
Long-term Efficacy of Emicizumab: Model-Based ABR for All Bleeds
All bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Model-Based ABR for All Bleeds1.6 (1.28 to 2.09)
SecondaryLong-term Efficacy of Emicizumab: Mean Calculated ABR for All Bleeds

The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Mean · All bleeds per year
Long-term Efficacy of Emicizumab: Mean Calculated ABR for All Bleeds
All bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Mean Calculated ABR for All Bleeds1.6 (0.14 to 6.61)
SecondaryLong-term Efficacy: Median Calculated ABR for All Bleeds

The number of all bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Median · All bleeds per year
Long-term Efficacy: Median Calculated ABR for All Bleeds
All bleeds per yearEmicizumab
Long-term Efficacy: Median Calculated ABR for All Bleeds1.1 (0.36 to 2.25)
SecondaryLong-term Efficacy of Emicizumab: Model-Based ABR for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Number · Treated joint bleeds per year
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Joint Bleeds0.2 (0.14 to 0.43)
SecondaryLong-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Mean · Treated joint bleeds per year
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Joint Bleeds0.2 (0.00 to 4.19)
SecondaryLong-term Efficacy of Emicizumab: Median Calculated ABR for Treated Joint Bleeds

The number of treated joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Median · Treated joint bleeds per year
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Joint Bleeds
Treated joint bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Joint Bleeds0.0 (0.00 to 0.29)
SecondaryLong-term Efficacy of Emicizumab: Model-Based ABR for Treated Target Joint Bleeds

The number of treated target joint bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Number · Treated target joint bleeds per year
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Target Joint Bleeds
Treated target joint bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Target Joint Bleeds0.1 (0.04 to 0.25)
SecondaryLong-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Target Joint Bleeds

The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Mean · Treated target joint bleeds per year
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Target Joint Bleeds
Treated target joint bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Target Joint Bleeds0.1 (0.00 to 3.89)
SecondaryLong-term Efficacy of Emicizumab: Median Calculated ABR for Treated Target Joint Bleeds

The number of treated target joint bleeds over the efficacy period is presented here as a calculated ABR that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated target joint bleed was defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry or an unresolved target joint (target joint that does not fulfil ≤2 bleeds into this joint within a consecutive 12-month period), and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Median · Treated target joint bleeds per year
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Target Joint Bleeds
Treated target joint bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Target Joint Bleeds0.0 (0.00 to 0.00)
SecondaryLong-term Efficacy of Emicizumab: Model-Based ABR for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period was estimated as an ABR using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Number · Treated spontaneous bleeds per year
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Model-Based ABR for Treated Spontaneous Bleeds0.2 (0.13 to 0.33)
SecondaryLong-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Mean · Treated spontaneous bleeds per year
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Mean Calculated ABR for Treated Spontaneous Bleeds0.2 (0.00 to 4.11)
SecondaryLong-term Efficacy of Emicizumab: Median Calculated ABR for Treated Spontaneous Bleeds

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

Time frame:
median [range, min-max] efficacy period: 156.07 [24.1-274] weeks
Reported as:
Median · Treated spontaneous bleeds per year
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Spontaneous Bleeds
Treated spontaneous bleeds per yearEmicizumab
Long-term Efficacy of Emicizumab: Median Calculated ABR for Treated Spontaneous Bleeds0.0 (0.00 to 0.35)
SecondaryCATCH Questionnaire for Adult Participants: Change From Baseline in the Daily Activity Risk Perception (RP) and Impact Domain Scores Over Time

Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the daily activity RP and impact domain has 48 items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing daily activities and higher impact of hemophilia on daily activities.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and Study completion (SC)/Early discontinuation (ED) (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Adult Participants: Change From Baseline in the Daily Activity Risk Perception (RP) and Impact Domain Scores Over Time
score on a scaleEmicizumab
Baseline20.93 ± 20.29
RP: Change at Week 13-2.31 ± 9.15
RP: Change at Week 25-2.48 ± 10.34
RP: Change at Week 37-5.05 ± 11.19
RP: Change at Week 49-2.58 ± 13.61
RP: Change at Week 61-3.50 ± 16.27
RP: Change at Week 73-3.54 ± 15.99
RP: Change at Week 85-8.32 ± 14.90
RP: Change at Week 97-6.08 ± 13.73
RP: Change at Week 109-5.94 ± 19.13
RP: Change at Week 121-9.86 ± 17.18
RP: Change at Week 133-7.26 ± 19.98
RP: Change at Week 145-7.28 ± 14.82
RP: Change at Week 157-8.36 ± 17.20
RP: Change at Week 169-9.93 ± 19.96
RP: Change at Week 181-19.16 ± NA
RP: Change at SC/ED-8.22 ± 21.31
Impact: Baseline23.56 ± 24.09
Impact: Change at Week 13-1.73 ± 10.37
Impact: Change at Week 25-1.83 ± 13.54
Impact: Change at Week 37-3.10 ± 14.89
Impact: Change at Week 49-2.80 ± 16.58
Impact: Change at Week 61-3.27 ± 18.75
Impact: Change at Week 73-4.29 ± 18.86
Impact: Change at Week 85-10.82 ± 17.90
Impact: Change at Week 97-9.20 ± 17.10
Impact: Change at Week 109-8.33 ± 21.50
Impact: Change at Week 121-11.14 ± 20.31
Impact: Change at Week 133-10.64 ± 23.84
Impact: Change at Week 145-12.33 ± 21.27
Impact: Change at Week 157-11.54 ± 26.76
Impact: Change at Week 169-14.32 ± 27.76
Impact: Change at Week 181-15.63 ± NA
Impact: Change at SC/ED-8.83 ± 27.56
SecondaryCATCH Questionnaire for Adult Participants: Change From Baseline in the Social Activity RP and Impact Domain Scores Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the social activity RP and impact domain has 22 items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing social activities and higher impact of hemophilia on social activities.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Adult Participants: Change From Baseline in the Social Activity RP and Impact Domain Scores Over Time
score on a scaleEmicizumab
Baseline22.41 ± 19.51
RP: Change at Week 131.52 ± 10.44
RP: Change at Week 25-1.05 ± 10.58
RP: Change at Week 37-3.29 ± 12.66
RP: Change at Week 49-2.35 ± 16.13
RP: Change at Week 61-4.19 ± 14.27
RP: Change at Week 73-3.38 ± 15.33
RP: Change at Week 85-6.06 ± 16.22
RP: Change at Week 97-5.59 ± 14.70
RP: Change at Week 109-3.79 ± 20.29
RP: Change at Week 121-8.62 ± 18.63
RP: Change at Week 133-8.10 ± 21.42
RP: Change at Week 145-7.13 ± 16.41
RP: Change at Week 157-8.46 ± 23.94
RP: Change at Week 169-11.39 ± 21.05
RP: Change at Week 181-18.33 ± NA
RP: Change at SC/DV-8.31 ± 22.19
Impact: Baseline26.39 ± 24.22
Impact: Change at Week 13-1.00 ± 12.00
Impact: Change at Week 25-2.04 ± 12.80
Impact: Change at Week 37-4.18 ± 16.17
Impact: Change at Week 49-1.86 ± 17.60
Impact: Change at Week 61-4.29 ± 19.21
Impact: Change at Week 73-4.47 ± 19.88
Impact: Change at Week 85-7.81 ± 18.73
Impact: Change at Week 97-7.38 ± 18.95
Impact: Change at Week 109-6.48 ± 24.94
Impact: Change at Week 121-10.30 ± 22.04
Impact: Change at Week 133-9.76 ± 25.28
Impact: Change at Week 145-11.35 ± 22.16
Impact: Change at Week 157-12.68 ± 32.58
Impact: Change at Week 169-15.08 ± 31.91
Impact: Change at Week 181-24.00 ± NA
Impact: Change at SC/DV-9.33 ± 28.42
SecondaryCATCH Questionnaire for Adult Participants: Change From Baseline in the Recreational Activity RP and Impact Domain Scores Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the recreational activity RP and impact domain has 32 items and a larger bank of additional items with each item scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale for both the RP and Impact. Higher scores indicating higher perceived risk of having a bleed while doing recreational activities and higher impact of hemophilia on recreational activities.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Adult Participants: Change From Baseline in the Recreational Activity RP and Impact Domain Scores Over Time
score on a scaleEmicizumab
Baseline44.51 ± 21.91
RP: Change at Week 13-9.29 ± 18.82
RP: Change at Week 25-0.01 ± 23.17
RP: Change at Week 37-8.67 ± 19.53
RP: Change at Week 49-6.35 ± 22.51
RP: Change at Week 61-8.47 ± 17.72
RP: Change at Week 73-5.23 ± 25.24
RP: Change at Week 85-6.04 ± 17.59
RP: Change at Week 97-6.89 ± 18.49
RP: Change at Week 109-10.14 ± 25.81
RP: Change at Week 121-10.51 ± 24.13
RP: Change at Week 133-14.54 ± 30.21
RP: Change at Week 145-12.55 ± 19.01
RP: Change at Week 157-8.89 ± 15.17
RP: Change at Week 169-20.50 ± 40.45
RP: Change at SC/DV-13.72 ± 22.31
Impact: Baseline40.24 ± 25.26
Impact: Change at Week 13-5.39 ± 25.22
Impact: Change at Week 25-1.75 ± 30.92
Impact: Change at Week 37-6.43 ± 27.73
Impact: Change at Week 49-2.68 ± 26.43
Impact: Change at Week 61-1.30 ± 25.30
Impact: Change at Week 73-4.75 ± 27.14
Impact: Change at Week 85-12.80 ± 22.10
Impact: Change at Week 97-8.97 ± 24.71
Impact: Change at Week 109-9.53 ± 29.53
Impact: Change at Week 121-11.65 ± 26.85
Impact: Change at Week 133-10.74 ± 37.09
Impact: Change at Week 145-0.98 ± 34.73
Impact: Change at Week 157-3.48 ± 30.49
Impact: Change at Week 169-38.28 ± 28.16
Impact: Change at SC/DV-16.94 ± 27.42
SecondaryCATCH Questionnaire for Adult Participants: Change From Baseline in the Work Impact (WI) and College Impact (CI) Domains Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥ 18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, work and college impact has 10 items and the items were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated impact of hemophilia on work and college activities.

Time frame:
WI: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks); CI: Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Adult Participants: Change From Baseline in the Work Impact (WI) and College Impact (CI) Domains Score Over Time
score on a scaleEmicizumab
Baseline30.83 ± 25.05
WI: Change at Week 13-4.85 ± 19.98
WI: Change at Week 25-2.32 ± 20.61
WI: Change at Week 37-1.44 ± 22.78
WI: Change at Week 49-2.14 ± 24.66
WI: Change at Week 61-6.78 ± 23.88
WI: Change at Week 73-5.02 ± 25.20
WI: Change at Week 85-6.81 ± 21.47
WI: Change at Week 97-6.52 ± 23.76
WI: Change at Week 109-11.53 ± 25.63
WI: Change at Week 121-12.54 ± 21.45
WI: Change at Week 133-6.97 ± 28.39
WI: Change at Week 145-16.78 ± 26.72
WI: Change at Week 157-15.96 ± 28.49
WI: Change at Week 169-12.63 ± 19.99
WI: Change at Week 181-25.67 ± NA
WI: Change at SC/DV-9.77 ± 18.79
CI: Baseline4.89 ± 2.12
CI: Change at Week 130 ± 0
CI: Change at Week 257.33 ± 6.35
CI: Change at Week 371.83 ± 7.78
CI: Change at Week 491.83 ± 2.59
CI: Change at Week 617.33 ± NA
CI: Change at Week 733.67 ± NA
CI: Change at Week 850 ± NA
CI: Change at Week 973.67 ± NA
CI: Change at Week 109-7.33 ± NA
CI: Change at Week 121-7.33 ± NA
CI: Change at Week 1333.67 ± NA
CI: Change at Week 145-3.67 ± NA
CI: Change at SC/DV-3.67 ± NA
SecondaryCATCH Questionnaire for Adult Participants: Change From Baseline in the Preoccupation Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, preoccupation has 10 items which were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Adult Participants: Change From Baseline in the Preoccupation Domain Score Over Time
score on a scaleEmicizumab
Baseline59.58 ± 29.11
Change at Week 13-2.34 ± 19.68
Change at Week 25-4.20 ± 19.11
Change at Week 37-7.88 ± 18.73
Change at Week 49-10.11 ± 16.33
Change at Week 61-10.80 ± 17.75
Change at Week 73-12.89 ± 17.00
Change at Week 85-15.05 ± 19.07
Change at Week 97-16.77 ± 20.20
Change at Week 109-15.02 ± 24.08
Change at Week 121-18.39 ± 19.88
Change at Week 133-16.38 ± 21.17
Change at Week 145-19.44 ± 20.48
Change at Week 157-15.56 ± 25.83
Change at Week 169-23.06 ± 28.39
Change at Week 181-75.00 ± NA
Change at SC/DV-16.44 ± 22.65
SecondaryCATCH Questionnaire for Adult Participants: Change From Baseline in the Treatment Burden Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, treatment burden has 8 items which were scored on 4 or 5 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater perceived burden of the hemophilia treatment.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Adult Participants: Change From Baseline in the Treatment Burden Domain Score Over Time
score on a scaleEmicizumab
Baseline37.09 ± 22.81
Change at Week 13-11.55 ± 20.91
Change at Week 25-13.84 ± 20.86
Change at Week 37-14.17 ± 21.16
Change at Week 49-10.22 ± 19.82
Change at Week 61-14.25 ± 19.53
Change at Week 73-15.15 ± 20.78
Change at Week 85-18.03 ± 25.79
Change at Week 97-20.97 ± 22.19
Change at Week 109-13.11 ± 23.03
Change at Week 121-18.89 ± 23.64
Change at Week 133-13.07 ± 25.96
Change at Week 145-17.36 ± 19.09
Change at Week 157-10.36 ± 21.06
Change at Week 169-18.48 ± 23.21
Change at Week 181-81.25 ± NA
Change at SC/ED-16.80 ± 24.71
SecondaryCATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain Associated With a Bleed Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consisting of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question: "Did you get a bleed in the past 7 days?" If the response was yes, participants were asked to rate their pain by selecting the number that best described the pain associated with the bleed. Data is reported only for categories/timepoints with non-zero values.

Time frame:
Baseline, Weeks 25, 49, 61, 85, 121, 133, 157 and 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Count of participants · Participants
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain Associated With a Bleed Over Time
ParticipantsEmicizumab
Baseline: Level-21
Baseline: Level-72
Baseline: Level-81
Week 25: Level-01
Week 25: Level-41
Week 25: Level-81
Week 49: Level-31
Week 61: Level-31
Week 61: Level-61
Week 85: Level-61
Week 85: Level-81
Week 121: Level-61
Week 121: Level-71
Week 133: Level-42
Week 133: Level-62
Week 157: Level-11
Week 169: Level-81
SC/ED: Level-31
SC/ED: Level-61
SecondaryCATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain in Target Joints Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Do you have target joints?" (If yes, please rate your pain by picking the number that best describes your pain in your target joint(s) over the past 7 days). Data is reported only for categories/timepoints with non-zero values.

Time frame:
Baseline, Weeks 1, 13, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
Reported as:
Count of participants · Participants
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain in Target Joints Over Time
ParticipantsEmicizumab
Baseline: Level-02
Baseline: Level-12
Baseline: Level-22
Baseline: Level-33
Baseline: Level-41
Baseline: Level-53
Baseline: Level-63
Baseline: Level-74
Baseline: Level-84
Baseline: Level-101
Week 1: Level-71
Week 13: Level-03
Week 13: Level-13
Week 13: Level-24
Week 13: Level-35
Week 13: Level-42
Week 13: Level-53
Week 13: Level-61
Week 13: Level-71
Week 13: Level-81
Week 13: Level-101
Week 25: Level-03
Week 25: Level-11
Week 25: Level-25
Week 25: Level-32
Week 25: Level-41
Week 25: Level-55
Week 25: Level-61
Week 25: Level-73
Week 25: Level-83
Week 25: Level-91
Week 37: Level-02
Week 37: Level-12
Week 37: Level-23
Week 37: Level-31
Week 37: Level-41
Week 37: Level-52
Week 37: Level-63
Week 37: Level-74
Week 37: Level-81
Week 37: Level-92
Week 49: Level-01
Week 49: Level-12
Week 49: Level-22
Week 49: Level-36
Week 49: Level-42
Week 49: Level-51
Week 49: Level-62
Week 49: Level-72
Week 49: Level-82
Week 61: Level-15
Week 61: Level-24
Week 61: Level-31
Week 61: Level-41
Week 61: Level-52
Week 61: Level-62
Week 61: Level-75
Week 61: Level-82
Week 61: Level-91
Week 73: Level-02
Week 73: Level-14
Week 73: Level-22
Week 73: Level-32
Week 73: Level-44
Week 73: Level-53
Week 73: Level-62
Week 73: Level-73
Week 73: Level-101
Week 85: Level-02
Week 85: Level-13
Week 85: Level-24
Week 85: Level-32
Week 85: Level-41
Week 85: Level-52
Week 85: Level-63
Week 85: Level-71
Week 85: Level-81
Week 85: Level-91
Week 97: Level-03
Week 97: Level-11
Week 97: Level-25
Week 97: Level-31
Week 97: Level-41
Week 97: Level-51
Week 97: Level-64
Week 97: Level-101
Week 109: Level-02
Week 109: Level-14
Week 109: Level-22
Week 109: Level-31
Week 109: Level-43
Week 109: Level-92
Week 109: Level-101
Week 121: Level-01
Week 121: Level-11
Week 121: Level-34
Week 121: Level-43
Week 121: Level-51
Week 121: Level-62
Week 121: Level-71
Week 121: Level-82
Week 133: Level-04
Week 133: Level-12
Week 133: Level-33
Week 133: Level-42
Week 133: Level-52
Week 133: Level-62
Week 133: Level-91
Week 133: Level-101
Week 145: Level-02
Week 145: Level-22
Week 145: Level-33
Week 145: Level-42
Week 145: Level-51
Week 145: Level-61
Week 145: Level-71
Week 157: Level-02
Week 157: Level-23
Week 157: Level-41
Week 157: Level-71
Week 169: Level-01
Week 169: Level-21
Week 169: Level-33
Week 169: Level-61
Week 181: Level-11
SC/ED: Level-01
SC/ED: Level-21
SC/ED: Level-31
SC/ED: Level-41
SC/ED: Level-54
SC/ED: Level-62
SC/ED: Level-72
SC/ED: Level-82
SecondaryCATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Worst Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its WORST over the past 7 days". Data is reported only for categories/timepoints with non-zero values.

Time frame:
Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
Reported as:
Count of participants · Participants
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Worst Over Time
ParticipantsEmicizumab
Baseline: Level-08
Baseline: Level-13
Baseline: Level-25
Baseline: Level-35
Baseline: Level-42
Baseline: Level-54
Baseline: Level-64
Baseline: Level-72
Baseline: Level-83
Baseline: Level-94
Week 1: Level-31
Week 1: Level-91
Week 13: Level-08
Week 13: Level-16
Week 13: Level-26
Week 13: Level-34
Week 13: Level-44
Week 13: Level-54
Week 13: Level-61
Week 13: Level-71
Week 13: Level-85
Week 13: Level-91
Week 25: Level-07
Week 25: Level-13
Week 25: Level-28
Week 25: Level-35
Week 25: Level-41
Week 25: Level-55
Week 25: Level-63
Week 25: Level-72
Week 25: Level-83
Week 25: Level-94
Week 37: Level-09
Week 37: Level-16
Week 37: Level-23
Week 37: Level-33
Week 37: Level-54
Week 37: Level-63
Week 37: Level-71
Week 37: Level-84
Week 37: Level-94
Week 37: Level-102
Week 49: Level-08
Week 49: Level-15
Week 49: Level-22
Week 49: Level-38
Week 49: Level-44
Week 49: Level-54
Week 49: Level-72
Week 49: Level-81
Week 49: Level-92
Week 49: Level-102
Week 61: Level-04
Week 61: Level-16
Week 61: Level-210
Week 61: Level-31
Week 61: Level-43
Week 61: Level-52
Week 61: Level-61
Week 61: Level-73
Week 61: Level-83
Week 61: Level-94
Week 61: Level-101
Week 73: Level-06
Week 73: Level-16
Week 73: Level-25
Week 73: Level-34
Week 73: Level-42
Week 73: Level-51
Week 73: Level-76
Week 73: Level-82
Week 73: Level-93
Week 73: Level-102
Week 85: Level-05
Week 85: Level-15
Week 85: Level-25
Week 85: Level-32
Week 85: Level-42
Week 85: Level-52
Week 85: Level-61
Week 85: Level-73
Week 85: Level-85
Week 85: Level-93
Week 97: Level-06
Week 97: Level-12
Week 97: Level-25
Week 97: Level-36
Week 97: Level-42
Week 97: Level-52
Week 97: Level-74
Week 97: Level-82
Week 109: Level-05
Week 109: Level-14
Week 109: Level-22
Week 109: Level-35
Week 109: Level-41
Week 109: Level-53
Week 109: Level-63
Week 109: Level-71
Week 109: Level-82
Week 109: Level-91
Week 109: Level-102
Week 121: Level-06
Week 121: Level-12
Week 121: Level-21
Week 121: Level-35
Week 121: Level-43
Week 121: Level-54
Week 121: Level-63
Week 121: Level-71
Week 121: Level-84
Week 121: Level-91
Week 121: Level-101
Week 133: Level-07
Week 133: Level-14
Week 133: Level-22
Week 133: Level-35
Week 133: Level-42
Week 133: Level-52
Week 133: Level-62
Week 133: Level-73
Week 133: Level-81
Week 133: Level-91
Week 133: Level-102
Week 145: Level-02
Week 145: Level-13
Week 145: Level-22
Week 145: Level-33
Week 145: Level-43
Week 145: Level-52
Week 145: Level-82
Week 145: Level-91
Week 145: Level-101
Week 157: Level-03
Week 157: Level-21
Week 157: Level-32
Week 157: Level-42
Week 157: Level-51
Week 157: Level-91
Week 169: Level-01
Week 169: Level-11
Week 169: Level-22
Week 169: Level-31
Week 169: Level-43
Week 169: Level-61
Week 169: Level-91
Week 181: Level-11
SC/ED: Level-08
SC/ED: Level-13
SC/ED: Level-22
SC/ED: Level-31
SC/ED: Level-54
SC/ED: Level-62
SC/ED: Level-71
SC/ED: Level-82
SC/ED: Level-92
SC/ED: Level-101
SecondaryCATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Least Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its LEAST over the past 7 days." Data is reported only for categories/timepoints with non-zero values.

Time frame:
Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
Reported as:
Count of participants · Participants
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Least Over Time
ParticipantsEmicizumab
Baseline: Level-013
Baseline: Level-17
Baseline: Level-27
Baseline: Level-35
Baseline: Level-44
Baseline: Level-51
Baseline: Level-61
Baseline: Level-71
Baseline: Level-91
Week 1: Level-21
Week 1: Level-31
Week 13: Level-015
Week 13: Level-111
Week 13: Level-23
Week 13: Level-32
Week 13: Level-45
Week 13: Level-53
Week 13: Level-61
Week 25: Level-020
Week 25: Level-15
Week 25: Level-26
Week 25: Level-33
Week 25: Level-43
Week 25: Level-52
Week 25: Level-62
Week 37: Level-016
Week 37: Level-16
Week 37: Level-26
Week 37: Level-33
Week 37: Level-42
Week 37: Level-53
Week 37: Level-62
Week 37: Level-81
Week 49: Level-015
Week 49: Level-17
Week 49: Level-22
Week 49: Level-39
Week 49: Level-43
Week 49: Level-61
Week 49: Level-71
Week 61: Level-015
Week 61: Level-18
Week 61: Level-21
Week 61: Level-34
Week 61: Level-42
Week 61: Level-54
Week 61: Level-62
Week 61: Level-72
Week 73: Level-015
Week 73: Level-110
Week 73: Level-24
Week 73: Level-32
Week 73: Level-41
Week 73: Level-55
Week 85: Level-012
Week 85: Level-18
Week 85: Level-25
Week 85: Level-31
Week 85: Level-43
Week 85: Level-53
Week 85: Level-81
Week 97: Level-014
Week 97: Level-13
Week 97: Level-26
Week 97: Level-32
Week 97: Level-42
Week 97: Level-51
Week 97: Level-71
Week 109: Level-012
Week 109: Level-15
Week 109: Level-24
Week 109: Level-35
Week 109: Level-51
Week 109: Level-61
Week 109: Level-101
Week 121: Level-011
Week 121: Level-15
Week 121: Level-26
Week 121: Level-33
Week 121: Level-43
Week 121: Level-51
Week 121: Level-61
Week 121: Level-71
Week 133: Level-011
Week 133: Level-16
Week 133: Level-23
Week 133: Level-34
Week 133: Level-43
Week 133: Level-51
Week 133: Level-62
Week 133: Level-71
Week 145: Level-05
Week 145: Level-16
Week 145: Level-24
Week 145: Level-31
Week 145: Level-41
Week 145: Level-51
Week 145: Level-61
Week 157: Level-03
Week 157: Level-11
Week 157: Level-24
Week 157: Level-41
Week 157: Level-51
Week 169: Level-04
Week 169: Level-12
Week 169: Level-23
Week 169: Level-31
Week 181: Level-21
SC/ED: Level-08
SC/ED: Level-14
SC/ED: Level-26
SC/ED: Level-32
SC/ED: Level-41
SC/ED: Level-54
SC/ED: Level-71
SecondaryCATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Least on the Average Over Time

CATCH was used to measure the effect of hemophilia and its treatment on adult participants (aged ≥18 years). The adult version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, work impact, preoccupation, treatment burden, and pain. Of this, the pain domain consists of five items, assessed using an 11-point numeric rating scale where 0 = no pain and 10 = pain as bad as you can imagine. The data reported here are from participants who answered the following question "Please rate your pain by picking the number that best describes your pain at its average over the past 7 days". Data is reported only for categories/timepoints with non-zero values.

Time frame:
Baseline, Weeks 1, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181 and SC/ED (up to approximately 274 weeks)
Reported as:
Count of participants · Participants
CATCH Questionnaire for Adult Participants: Number of Participants by Responses to Their Level of Pain at Its Least on the Average Over Time
ParticipantsEmicizumab
Baseline: Level-09
Baseline: Level-14
Baseline: Level-24
Baseline: Level-37
Baseline: Level-45
Baseline: Level-51
Baseline: Level-65
Baseline: Level-74
Baseline: Level-81
Week 1: Level-31
Week 1: Level-61
Week 13: Level-09
Week 13: Level-19
Week 13: Level-26
Week 13: Level-35
Week 13: Level-41
Week 13: Level-55
Week 13: Level-61
Week 13: Level-73
Week 13: Level-81
Week 25: Level-010
Week 25: Level-110
Week 25: Level-25
Week 25: Level-32
Week 25: Level-47
Week 25: Level-63
Week 25: Level-72
Week 25: Level-82
Week 37: Level-09
Week 37: Level-17
Week 37: Level-25
Week 37: Level-33
Week 37: Level-43
Week 37: Level-52
Week 37: Level-66
Week 37: Level-73
Week 37: Level-81
Week 49: Level-09
Week 49: Level-17
Week 49: Level-23
Week 49: Level-38
Week 49: Level-45
Week 49: Level-51
Week 49: Level-62
Week 49: Level-73
Week 61: Level-07
Week 61: Level-110
Week 61: Level-25
Week 61: Level-33
Week 61: Level-41
Week 61: Level-53
Week 61: Level-65
Week 61: Level-72
Week 61: Level-82
Week 73: Level-08
Week 73: Level-19
Week 73: Level-25
Week 73: Level-32
Week 73: Level-43
Week 73: Level-55
Week 73: Level-62
Week 73: Level-72
Week 73: Level-91
Week 85: Level-07
Week 85: Level-16
Week 85: Level-24
Week 85: Level-33
Week 85: Level-43
Week 85: Level-55
Week 85: Level-63
Week 85: Level-71
Week 85: Level-81
Week 97: Level-08
Week 97: Level-16
Week 97: Level-25
Week 97: Level-33
Week 97: Level-55
Week 97: Level-62
Week 109: Level-04
Week 109: Level-19
Week 109: Level-24
Week 109: Level-35
Week 109: Level-43
Week 109: Level-61
Week 109: Level-72
Week 109: Level-91
Week 121: Level-06
Week 121: Level-15
Week 121: Level-23
Week 121: Level-34
Week 121: Level-45
Week 121: Level-55
Week 121: Level-62
Week 121: Level-71
Week 133: Level-08
Week 133: Level-16
Week 133: Level-25
Week 133: Level-32
Week 133: Level-43
Week 133: Level-52
Week 133: Level-62
Week 133: Level-71
Week 133: Level-81
Week 133: Level-91
Week 145: Level-02
Week 145: Level-14
Week 145: Level-24
Week 145: Level-32
Week 145: Level-41
Week 145: Level-53
Week 145: Level-62
Week 145: Level-71
Week 157: Level-03
Week 157: Level-11
Week 157: Level-22
Week 157: Level-32
Week 157: Level-41
Week 157: Level-71
Week 169: Level-02
Week 169: Level-11
Week 169: Level-22
Week 169: Level-33
Week 169: Level-52
Week 181: Level-11
SC/ED: Level-08
SC/ED: Level-14
SC/ED: Level-22
SC/ED: Level-32
SC/ED: Level-43
SC/ED: Level-51
SC/ED: Level-64
SC/ED: Level-82
SecondaryCATCH Questionnaire for Pediatric Participants: Change From Baseline in the Daily Activity RP and Impact Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, daily activity RP and impact has 38 items with each item scored on 3 or 4 points ordinal scale. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicating higher perceived risk of having a bleed while doing daily activities and higher impact of hemophilia on daily activities.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Daily Activity RP and Impact Domain Score Over Time
score on a scaleEmicizumab
Baseline7.50 ± 8.89
RP: Change at Week 13-4.11 ± 7.71
RP: Change at Week 25-3.93 ± 8.10
RP: Change at Week 37-3.76 ± 11.99
RP: Change at Week 49-3.04 ± 11.60
RP: Change at Week 61-1.79 ± 11.96
RP: Change at Week 73-3.77 ± 12.46
RP: Change at Week 85-2.58 ± 10.59
RP: Change at Week 97-2.26 ± 11.56
RP: Change at Week 1090.79 ± 12.88
RP: Change at Week 121-0.56 ± 14.74
RP: Change at Week 133-2.46 ± 13.09
RP: Change at Week 1453.57 ± 16.47
RP: Change at Week 157-5.10 ± 8.95
RP: Change at Week 169-9.52 ± 5.46
RP: Change at SC/ED-0.22 ± 13.83
Impact: Baseline6.01 ± 12.94
Impact: Change at Week 13-2.48 ± 10.19
Impact: Change at Week 25-1.18 ± 9.03
Impact: Change at Week 37-2.11 ± 16.58
Impact: Change at Week 490.24 ± 13.35
Impact: Change at Week 61-0.23 ± 12.92
Impact: Change at Week 73-0.26 ± 13.14
Impact: Change at Week 85-1.18 ± 11.30
Impact: Change at Week 97-0.50 ± 11.98
Impact: Change at Week 1090 ± 13.01
Impact: Change at Week 1210.62 ± 12.70
Impact: Change at Week 133-0.59 ± 13.70
Impact: Change at Week 1452.36 ± 14.94
Impact: Change at Week 157-5.72 ± 9.22
Impact: Change at Week 169-6.29 ± 8.92
Impact: Change at SC/ED2.80 ± 13.12
SecondaryCATCH Questionnaire for Pediatric Participants: Change From Baseline in the Social Activity Risk Perception and Impact Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, social activity RP and impact has 16 items which were scored on 3 or 4 points ordinal scale. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher perceived risk of having a bleed while doing social activities and higher impact of hemophilia on social activities.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Social Activity Risk Perception and Impact Domain Score Over Time
score on a scaleEmicizumab
Baseline16.79 ± 15.76
RP: Change at Week 13-5.36 ± 12.45
RP: Change at Week 25-4.64 ± 14.15
RP: Change at Week 37-4.51 ± 16.87
RP: Change at Week 49-4.29 ± 16.29
RP: Change at Week 61-3.93 ± 15.63
RP: Change at Week 73-7.94 ± 17.65
RP: Change at Week 85-7.94 ± 19.58
RP: Change at Week 97-5.26 ± 18.42
RP: Change at Week 109-5.16 ± 21.75
RP: Change at Week 121-3.38 ± 19.10
RP: Change at Week 133-5.36 ± 21.59
RP: Change at Week 145-2.98 ± 20.31
RP: Change at Week 157-5.10 ± 8.95
RP: Change at Week 169-4.76 ± 8.25
RP: Change at SC/DV-6.25 ± 19.67
Impact: Baseline7.07 ± 8.45
Impact: Change at Week 13-0.70 ± 7.70
Impact: Change at Week 25-0.94 ± 8.04
Impact: Change at Week 370.76 ± 12.82
Impact: Change at Week 491.19 ± 13.44
Impact: Change at Week 610.01 ± 11.87
Impact: Change at Week 731.06 ± 15.48
Impact: Change at Week 851.07 ± 15.62
Impact: Change at Week 973.24 ± 15.51
Impact: Change at Week 1090.53 ± 14.91
Impact: Change at Week 1213.25 ± 17.21
Impact: Change at Week 1330.29 ± 16.01
Impact: Change at Week 1450.79 ± 15.15
Impact: Change at Week 157-1.35 ± 10.44
Impact: Change at Week 169-6.29 ± 7.20
Impact: Change at SC/DV2.06 ± 14.50
SecondaryCATCH Questionnaire for Pediatric Participants: Change From Baseline in the Recreational Activity RP and Impact Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, recreational activity RP \& impact has 34 items + larger bank of additional items. The items were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher perceived risk of having a bleed while doing recreational activities and higher impact of hemophilia on recreational activities.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Recreational Activity RP and Impact Domain Score Over Time
score on a scaleEmicizumab
Baseline41.57 ± 29.94
RP: Change at Week 13-11.17 ± 23.16
RP: Change at Week 25-7.47 ± 24.89
RP: Change at Week 37-14.15 ± 32.78
RP: Change at Week 49-9.34 ± 28.14
RP: Change at Week 61-13.53 ± 29.67
RP: Change at Week 73-17.14 ± 30.77
RP: Change at Week 85-14.09 ± 29.91
RP: Change at Week 97-12.47 ± 33.00
RP: Change at Week 109-15.95 ± 33.99
RP: Change at Week 121-12.75 ± 35.83
RP: Change at Week 133-11.23 ± 34.77
RP: Change at Week 145-12.34 ± 35.96
RP: Change at Week 1570.73 ± 9.57
RP: Change at Week 1692.08 ± 3.61
RP: Change at SC/ED-13.32 ± 34.32
Impact: Baseline14.51 ± 14.70
Impact: Change at Week 133.75 ± 16.90
Impact: Change at Week 253.07 ± 15.32
Impact: Change at Week 37-0.38 ± 25.40
Impact: Change at Week 49-0.50 ± 20.97
Impact: Change at Week 61-1.41 ± 19.66
Impact: Change at Week 73-5.04 ± 18.33
Impact: Change at Week 852.86 ± 19.71
Impact: Change at Week 974.89 ± 24.38
Impact: Change at Week 1090.33 ± 21.54
Impact: Change at Week 1210.93 ± 26.46
Impact: Change at Week 1333.58 ± 27.64
Impact: Change at Week 145-1.92 ± 14.97
Impact: Change at Week 157-1.75 ± 10.66
Impact: Change at Week 169-8.25 ± 14.29
Impact: Change at SC/ED4.17 ± 19.76
SecondaryCATCH Questionnaire for Pediatric Participants: Change From Baseline in the School Impact Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, school impact has 11 items and the items were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated higher impact of hemophilia on school activities.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the School Impact Domain Score Over Time
score on a scaleEmicizumab
Baseline12.86 ± 8.45
Change at Week 13-1.29 ± 6.99
Change at Week 25-0.71 ± 16.49
Change at Week 373.32 ± 13.07
Change at Week 49-0.17 ± 7.91
Change at Week 610.99 ± 12.02
Change at Week 734.92 ± 22.04
Change at Week 85-0.19 ± 10.28
Change at Week 974.62 ± 19.21
Change at Week 1090.39 ± 10.45
Change at Week 121-0.18 ± 11.64
Change at Week 1330.22 ± 11.68
Change at Week 1458.47 ± 24.48
Change at Week 157-4.71 ± 8.27
Change at Week 169-7.67 ± 6.93
Change at SC/ED1.41 ± 8.68
SecondaryCATCH Questionnaire for Pediatric Participants: Change From Baseline in the Preoccupation Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, preoccupation has 3 items which were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Preoccupation Domain Score Over Time
score on a scaleEmicizumab
Baseline47.98 ± 25.81
Change at Week 13-2.38 ± 40.16
Change at Week 25-7.43 ± 30.68
Change at Week 37-6.18 ± 26.73
Change at Week 49-10.75 ± 31.03
Change at Week 61-9.10 ± 27.77
Change at Week 73-3.58 ± 30.98
Change at Week 85-11.89 ± 28.42
Change at Week 97-15.66 ± 33.94
Change at Week 109-11.03 ± 26.79
Change at Week 121-18.26 ± 29.27
Change at Week 133-19.66 ± 29.92
Change at Week 145-20.71 ± 32.67
Change at Week 157-25.93 ± 38.41
Change at Week 169-11.00 ± 9.53
Change at SC/ED-8.16 ± 31.05
SecondaryCATCH Questionnaire for Pediatric Participants: Change From Baseline in the Treatment Burden Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, treatment burden has 7 items which were scored on 3 or 4 points ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept \& applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated lower perceived burden of the hemophilia treatment.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Pediatric Participants: Change From Baseline in the Treatment Burden Domain Score Over Time
score on a scaleEmicizumab
Baseline38.91 ± 27.98
Change at Week 1313.30 ± 26.72
Change at Week 2518.29 ± 26.56
Change at Week 3716.25 ± 30.54
Change at Week 499.67 ± 29.57
Change at Week 6114.13 ± 30.50
Change at Week 7315.95 ± 30.08
Change at Week 8521.54 ± 33.68
Change at Week 9718.64 ± 32.00
Change at Week 10916.62 ± 33.45
Change at Week 12119.25 ± 35.00
Change at Week 13315.92 ± 30.53
Change at Week 1459.71 ± 30.57
Change at Week 15718.21 ± 26.17
Change at Week 1691.83 ± 16.17
Change at SC/ED16.63 ± 36.63
SecondaryCATCH Questionnaire for Pediatric Participants: Number of Participants by Responses to Their Level of Hurt Associated With a Bleed Over Time

CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain). Of this, pain domain (Hurt) consists of two items, assessed using an 11-point numeric rating scale where 0 = no hurt and 10 = a lot of hurt. The data reported here are from participants who answered the following question "Did you get a bleed in the past 7 days? ( If yes, how much did the bleed hurt?)." Data is reported only for categories/timepoints with non-zero values.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 85, 97, 109, 121, 133, 145 and 157
Reported as:
Count of participants · Participants
CATCH Questionnaire for Pediatric Participants: Number of Participants by Responses to Their Level of Hurt Associated With a Bleed Over Time
ParticipantsEmicizumab
Baseline: Level-41
Baseline: Level-51
Baseline: Level-91
Week 13: Level-11
Week 25: Level-61
Week 37: Level-31
Week 49: Level-61
Week 61: Level-71
Week 61: Level-81
Week 85: Level-11
Week 97: Level-01
Week 97: Level-31
Week 109: Level-12
Week 109: Level-42
Week 121: Level-61
Week 121: Level-81
Week 133: Level-21
Week 145: Level-71
Week 157: Level-51
SecondaryCATCH Questionnaire for Pediatric Participants: Number of Participants by Responses to Their Level of Hurt at Its Worst Over Time

CATCH was used to measure the effect of hemophilia and its treatment on pediatric participants (aged 8-17 years). The pediatric version has 7 domains (daily activity RP and impact, social activity RP and impact, recreational activity RP and impact, school impact, preoccupation, treatment burden, and pain. Of this, pain domain (Hurt) consists of two items, assessed using an 11-point numeric rating scale where 0 = no hurt and 10 = a lot of hurt. The data reported here are from participants who answered the following question "What is the WORST that your body has hurt over the past 7 days". Data is reported only for categories/timepoints with non-zero values.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145,157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Count of participants · Participants
CATCH Questionnaire for Pediatric Participants: Number of Participants by Responses to Their Level of Hurt at Its Worst Over Time
ParticipantsEmicizumab
Baseline: Level-03
Baseline: Level-15
Baseline: Level-23
Baseline: Level-32
Baseline: Level-41
Baseline: Level-52
Baseline: Level-71
Baseline: Level-81
Baseline: Level-91
Week 13: Level-09
Week 13: Level-13
Week 13: Level-22
Week 13: Level-32
Week 13: Level-41
Week 13: Level-81
Week 13: Level-91
Week 25: Level-08
Week 25: Level-11
Week 25: Level-24
Week 25: Level-32
Week 25: Level-52
Week 25: Level-62
Week 37: Level-03
Week 37: Level-14
Week 37: Level-23
Week 37: Level-35
Week 37: Level-42
Week 37: Level-61
Week 49: Level-05
Week 49: Level-12
Week 49: Level-24
Week 49: Level-31
Week 49: Level-42
Week 49: Level-53
Week 49: Level-71
Week 49: Level-81
Week 61: Level-06
Week 61: Level-11
Week 61: Level-21
Week 61: Level-32
Week 61: Level-43
Week 61: Level-51
Week 61: Level-62
Week 61: Level-72
Week 61: Level-81
Week 61: Level-91
Week 73: Level-04
Week 73: Level-12
Week 73: Level-23
Week 73: Level-32
Week 73: Level-42
Week 73: Level-64
Week 73: Level-71
Week 85: Level-04
Week 85: Level-13
Week 85: Level-21
Week 85: Level-32
Week 85: Level-42
Week 85: Level-51
Week 85: Level-63
Week 85: Level-71
Week 85: Level-81
Week 97: Level-05
Week 97: Level-12
Week 97: Level-22
Week 97: Level-31
Week 97: Level-41
Week 97: Level-53
Week 97: Level-62
Week 97: Level-73
Week 109: Level-03
Week 109: Level-13
Week 109: Level-23
Week 109: Level-32
Week 109: Level-43
Week 109: Level-52
Week 109: Level-81
Week 109: Level-101
Week 121: Level-03
Week 121: Level-12
Week 121: Level-21
Week 121: Level-32
Week 121: Level-42
Week 121: Level-54
Week 121: Level-63
Week 121: Level-82
Week 133: Level-03
Week 133: Level-11
Week 133: Level-26
Week 133: Level-42
Week 133: Level-52
Week 133: Level-61
Week 133: Level-101
Week 145: Level-02
Week 145: Level-11
Week 145: Level-23
Week 145: Level-31
Week 145: Level-53
Week 145: Level-81
Week 145: Level-101
Week 157: Level-03
Week 157: Level-21
Week 157: Level-31
Week 157: Level-41
Week 157: Level-51
Week 169: Level-01
Week 169: Level-11
Week 169: Level-31
SC/ED: Level-03
SC/ED: Level-11
SC/ED: Level-25
SC/ED: Level-52
SC/ED: Level-63
SC/ED: Level-82
SecondaryCATCH Questionnaire for Caregivers: Change From Baseline in the Preoccupation Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on caregivers of pediatric participants (aged \<8 years). The caregiver version has 2 domains (preoccupation and treatment burden). Of this, preoccupation has 13 items with each of the items were scored on 4 or 5 ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater preoccupation related to hemophilia.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Caregivers: Change From Baseline in the Preoccupation Domain Score Over Time
score on a scaleEmicizumab
Baseline53.54 ± 17.84
Change at Week 13-6.02 ± 11.48
Change at Week 25-9.95 ± 10.09
Change at Week 37-10.00 ± 15.40
Change at Week 49-8.75 ± 14.46
Change at Week 61-10.42 ± 13.50
Change at Week 73-17.71 ± 12.10
Change at Week 85-15.28 ± 11.83
Change at Week 97-11.72 ± 14.64
Change at Week 109-16.46 ± 11.68
Change at Week 121-10.21 ± 11.09
Change at Week 133-15.89 ± 17.07
Change at Week 145-17.59 ± 17.53
Change at Week 157-22.50 ± 19.62
Change at Week 169-22.92 ± 7.51
Change at SC/ED-15.42 ± 18.67
SecondaryCATCH Questionnaire for Caregivers: Change From Baseline in the Treatment Burden Domain Score Over Time

CATCH was used to measure the effect of hemophilia and its treatment on caregivers of pediatric participants (aged \<8 years). The caregiver version has 2 domains (preoccupation and treatment burden). Of this, treatment burden has 8 items which were scored on 4 or 5 ordinal scales. Raw domain scores were obtained by calculating the mean of the item scores for all items within the corresponding concept and applying a linear transformation. The transformed scores range from 0-100 scale. Higher scores indicated greater perceived burden of the hemophilia treatment.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
CATCH Questionnaire for Caregivers: Change From Baseline in the Treatment Burden Domain Score Over Time
score on a scaleEmicizumab
Baseline43.93 ± 21.50
Change at Week 13-13.49 ± 16.34
Change at Week 25-18.65 ± 16.44
Change at Week 37-20.00 ± 14.79
Change at Week 49-19.64 ± 19.65
Change at Week 61-28.97 ± 15.51
Change at Week 73-26.79 ± 19.75
Change at Week 85-28.17 ± 19.27
Change at Week 97-21.88 ± 20.24
Change at Week 109-22.14 ± 24.44
Change at Week 121-21.43 ± 28.22
Change at Week 133-23.66 ± 16.85
Change at Week 145-22.62 ± 18.90
Change at Week 157-24.29 ± 14.15
Change at Week 169-28.57 ± 18.56
Change at SC/ED-28.57 ± 23.01
SecondaryPercentage of Participants Who Prefer Emicizumab SC Treatment, Their Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Week 17

The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with subcutaneous (SC) emicizumab, intravenous (IV) factor VIIII (FVIII), or no preference. The 95% confidence intervals were calculated using the Pearson-Clopper method.

Time frame:
Week 17
Reported as:
Number · Percentage of participants
Percentage of Participants Who Prefer Emicizumab SC Treatment, Their Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Week 17
Percentage of participantsEmicizumab
Prefer the New Study Drug Treatment (Emicizumab SC)96.2 (86.79 to 99.53)
Prefer My Old Hemophilia Treatment (IV)1.9 (0.05 to 10.26)
Have No Preference1.9 (0.05 to 10.26)
SecondaryPercentage of Caregivers Who Prefer Emicizumab SC Treatment, Their Child's Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Week 17

The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the caregiver's preference for their child's treatment with subcutaneous (SC) emicizumab, intravenous (IV) factor VIIII (FVIII), or no preference. The 95% confidence intervals were calculated using the Pearson-Clopper method.

Time frame:
Week 17
Reported as:
Number · Percentage of caregivers
Percentage of Caregivers Who Prefer Emicizumab SC Treatment, Their Child's Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Week 17
Percentage of caregiversEmicizumab
Prefer the New Study Drug Treatment (Emicizumab SC)85.7 (67.33 to 95.97)
Prefer My Child's Old Hemophilia Treatment (IV)3.6 (0.09 to 18.35)
Have No Preference10.7 (2.27 to 28.23)
SecondaryChange From Baseline in Hemophilia Joint Health Scores Over Time

The HJHS measures joint health of the joints (knees, ankles, and elbows) most commonly affected by bleeding in hemophilia. The HJHS 2.1 provides joint specific total scores which are added to obtain the sum of joints totals and also a global gait score. These two scores are then added to obtain HJHS total score. The minimum score per joint is 0, the maximum score is 20. In addition, Gait is scored on a scale from 0 to 4 based on the number of skills that are not within the normal limits. The total score is the sum of scores across all six joints plus the gait score (range from 0 to 124, with 0 being normal and 124 being the most severe disease). A higher score indicates worse joint health.

Time frame:
Baseline, Weeks 13, 25, 37, 49, 61, 73, 85, 97, 109,121, 133, 145, 157, 169 and SC/ED (up to approximately 274 weeks)
Reported as:
Mean · score on a scale
Change From Baseline in Hemophilia Joint Health Scores Over Time
score on a scaleEmicizumab
Baseline7.57 ± 10.51
Change at Week 25-1.20 ± 3.10
Change at Week 290 ± 0
Change at Week 49-1.31 ± 3.65
Change at Week 73-1.15 ± 4.02
Change at Week 97-1.40 ± 3.33
Change at Week 121-0.96 ± 3.61
Change at Week 145-2.00 ± 3.68
Change at Week 169-2.50 ± 4.45
Change at SC/ED1.42 ± 3.95
SecondaryChange From Baseline in Mean Daily Peak Activity Duration Over Time

For physical activity assessment, participants ≥5 years of age were instructed to wear the study accelerometry device on the wrist continuously (24 hours/day) every day for the designated 2-week periods during the study. A participant was considered to be compliant with the physical activity assessments if they wore the study device continuously (≥8 hours/day) every day for at least 8 days of each of the designated 2-week periods during the study. If this compliance criterion was not reached at a specific timepoint the participant was not included in the analysis of the designated 2-week periods where compliance was not reached. Daily measurements were averaged over the 14-days timepoint. Activity count was a measure of the acceleration measured by the device. The daily peak activity duration was defined as the sum of moderate to vigorous activity per day (in minutes).

Time frame:
Baseline (Weeks 1-2) and Weeks 13 (Weeks 12-13 period), 25 (Weeks 24-25 period), 37 (Weeks 36-37 period), and 49 (Weeks 48-49 period)
Reported as:
Mean · Minutes per day
Change From Baseline in Mean Daily Peak Activity Duration Over Time
Minutes per dayParticipants ≥5 Years Old: EmicizumabParticipants ≥5 to <18 Years Old: EmicizumabParticipants ≥18 Years Old: Emicizumab
Baseline (BL) - Value at Visit130 ± 56168 ± 66108 ± 35
Change from BL at Week 13-2 ± 34-4 ± 42-1 ± 29
Change from BL at Week 254 ± 53-4 ± 748 ± 37
Change from BL at Week 3714 ± 5517 ± 7312 ± 40
Change from BL at Week 4917 ± 4019 ± 5116 ± 34
SecondaryChange From Baseline in Mean Daily Step Count Over Time

For physical activity assessment, participants ≥5 years of age were instructed to wear the study accelerometry device on the wrist continuously (24 hours/day) every day for the designated 2-week periods during the study. A participant was considered to be compliant with the physical activity assessments if they wore the study device continuously (≥8 hours/day) every day for at least 8 days of each of the designated 2-week periods during the study. If this compliance criterion was not reached at a specific timepoint the participant was not included in the analysis of the designated 2-week periods where compliance was not reached. Daily measurements were averaged over the 14-days timepoint. Activity count was a measure of the acceleration measured by the device.

Time frame:
Baseline (Weeks 1-2) and Weeks 13 (Weeks 12-13), 25 (Weeks 24-25), 37 (Weeks 36-37), and 49 (Weeks 48-49)
Reported as:
Mean · Step count per day
Change From Baseline in Mean Daily Step Count Over Time
Step count per dayParticipants ≥5 Years Old: EmicizumabParticipants ≥5 to <18 Years Old: EmicizumabParticipants ≥18 Years Old: Emicizumab
Baseline (BL) - Value at Visit6441 ± 26176755 ± 31686263 ± 2276
Change from BL at Week 1344 ± 1846-18 ± 236187 ± 1423
Change from BL at Week 25119 ± 2977-69 ± 4348225 ± 1901
Change from BL at Week 37767 ± 31891403 ± 4544356 ± 1852
Change from BL at Week 491216 ± 24401740 ± 3130919 ± 1945
SecondaryMenstrual Bleed Questionnaire (MBQ) for Female Participants of Childbearing Potential: Change From Baseline in the MBQ Total Score Over Time

The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The MBQ score ranges from 0 to 75. Higher scores indicate a worse quality of life and more severe symptoms.

Time frame:
Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and145
Reported as:
Mean · score on scale
Menstrual Bleed Questionnaire (MBQ) for Female Participants of Childbearing Potential: Change From Baseline in the MBQ Total Score Over Time
score on scaleEmicizumab
Baseline26.00 ± 8.49
Change at Week 5-13.50 ± 20.51
Change at Week 9-12.50 ± 9.19
Change at Week 13-12.00 ± 5.66
Change at Week 17-12.00 ± 12.73
Change at Week 21-15.00 ± 12.73
Change at Week 25-13.50 ± 9.19
Change at Week 29-10.50 ± 7.78
Change at Week 33-18.50 ± 10.61
Change at Week 37-17.00 ± 8.49
Change at Week 41-13.50 ± 9.19
Change at Week 45-15.00 ± 11.31
Change at Week 49-21.00 ± NA
Change at Week 53 (n=1)-20.00 ± NA
Change at Week 57-21.00 ± NA
Change at Week 61-17.50 ± 10.61
Change at Week 65-17.50 ± 6.36
Change at Week 69-16.00 ± 9.90
Change at Week 73-15.50 ± 10.61
Change at Week 77-8.00 ± NA
Change at Week 81-9.00 ± NA
Change at Week 85-10.00 ± NA
Change at Week 89-7.00 ± NA
Change at Week 93-6.00 ± NA
Change at Week 97-11.00 ± NA
Change at Week 101-8.00 ± NA
Change at Week 104-8.00 ± NA
Change at Week 109-10.00 ± NA
Change at Week 113-9.00 ± NA
Change at Week 117-9.00 ± NA
Change at Week 121-9.00 ± NA
Change at Week 125-9.00 ± NA
Change at Week 129-11.00 ± NA
Change at Week 133-9.00 ± NA
Change at Week 137-11.00 ± NA
Change at Week 141-13.00 ± NA
Change at Week 145-13.00 ± NA
SecondaryMBQ for Female Participants of Childbearing Potential: Change From Baseline in the Heaviness Subscale Score Over Time

The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for heaviness subscale ranges from 0 to 29. Higher score indicates more heavy bleeding.

Time frame:
Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 89, 93, 97, 101, 104, 109, 113, 121, 125, 129, 133 and 137 (up to approximately 274 weeks)
Reported as:
Mean · score on scale
MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Heaviness Subscale Score Over Time
score on scaleEmicizumab
Baseline9.50 ± 4.95
Change at Week 5-1.00 ± NA
Change at Week 9-5.50 ± 3.54
Change at Week 13-4.50 ± 2.12
Change at Week 17-5.00 ± 5.66
Change at Week 21-7.50 ± 4.95
Change at Week 25-4.00 ± NA
Change at Week 29-5.50 ± 3.54
Change at Week 33-9.00 ± 4.24
Change at Week 37-9.00 ± 4.24
Change at Week 41-4.00 ± NA
Change at Week 45-7.00 ± 7.07
Change at Week 49-11.00 ± NA
Change at Week 53-9.00 ± NA
Change at Week 57-10.00 ± NA
Change at Week 61-5.00 ± NA
Change at Week 65-11.00 ± NA
Change at Week 69-8.50 ± 4.95
Change at Week 73-7.50 ± 6.36
Change at Week 77-4.00 ± NA
Change at Week 81-5.00 ± NA
Change at Week 89-3.00 ± NA
Change at Week 93-3.00 ± NA
Change at Week 97-5.00 ± NA
Change at Week 101-4.00 ± NA
Change at Week 104-4.00 ± NA
Change at Week 109-5.00 ± NA
Change at Week 113-5.00 ± NA
Change at Week 121-5.00 ± NA
Change at Week 125-5.00 ± NA
Change at Week 129-6.00 ± NA
Change at Week 133-5.00 ± NA
Change at Week 137-5.00 ± NA
SecondaryMBQ for Female Participants of Childbearing Potential: Change From Baseline in the QoL Subscale Score Over Time

The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for QoL subscale ranges from 0 to 37. Higher scores indicate a worse QoL.

Time frame:
Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and 145
Reported as:
Mean · score on scale
MBQ for Female Participants of Childbearing Potential: Change From Baseline in the QoL Subscale Score Over Time
score on scaleEmicizumab
Baseline11.00 ± 2.83
Change at Week 5-5.50 ± 10.61
Change at Week 9-5.50 ± 7.78
Change at Week 13-5.00 ± 5.66
Change at Week 17-5.00 ± 7.07
Change at Week 21-6.00 ± 9.90
Change at Week 25-3.00 ± 4.24
Change at Week 29-3.50 ± 4.95
Change at Week 33-6.00 ± 5.66
Change at Week 37-6.00 ± 5.66
Change at Week 41-3.00 ± 4.24
Change at Week 45-5.50 ± 4.95
Change at Week 49-9.00 ± NA
Change at Week 53-10.00 ± NA
Change at Week 57-10.00 ± NA
Change at Week 61-6.00 ± 5.66
Change at Week 65-6.50 ± 4.95
Change at Week 69-6.00 ± 5.66
Change at Week 73-6.00 ± 5.66
Change at Week 77-2.00 ± NA
Change at Week 81-2.00 ± NA
Change at Week 85-3.00 ± NA
Change at Week 89-3.00 ± NA
Change at Week 93-2.00 ± NA
Change at Week 97-4.00 ± NA
Change at Week 101-3.00 ± NA
Change at Week 104-3.00 ± NA
Change at Week 109-3.00 ± NA
Change at Week 113-3.00 ± NA
Change at Week 121-3.00 ± NA
Change at Week 125-3.00 ± NA
Change at Week 129-3.00 ± NA
Change at Week 133-3.00 ± NA
Change at Week 137-4.00 ± NA
Change at Week 141-4.00 ± NA
Change at Week 145-4.00 ± NA
SecondaryMBQ for Female Participants of Childbearing Potential: Change From Baseline in the Irregularity Subscale Score Over Time

The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for irregularity subscale ranges from 0 to 6. Higher score indicates more irregularity.

Time frame:
Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 104, 109, 113, 117, 121, 125, 129, 133, 137, 141 and 145
Reported as:
Mean · score on scale
MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Irregularity Subscale Score Over Time
score on scaleEmicizumab
Baseline4.00 ± 1.41
Change at Week 50 ± 1.41
Change at Week 9-0.50 ± 0.71
Change at Week 13-1.50 ± 0.71
Change at Week 17-1.50 ± 0.71
Change at Week 21-1.00 ± 0
Change at Week 25-0.50 ± 0.71
Change at Week 29-0.50 ± 0.71
Change at Week 33-2.50 ± 2.12
Change at Week 37-1.50 ± 0.71
Change at Week 41-0.50 ± 0.71
Change at Week 45-1.50 ± 0.71
Change at Week 49-1.00 ± NA
Change at Week 53-1.00 ± NA
Change at Week 57-1.00 ± NA
Change at Week 61-1.00 ± 0
Change at Week 65-1.50 ± 0.71
Change at Week 69-0.50 ± 0.71
Change at Week 73-1.00 ± 0
Change at Week 851.00 ± NA
Change at Week 930 ± NA
Change at Week 970 ± NA
Change at Week 1010 ± NA
Change at Week 1040 ± NA
Change at Week 1130 ± NA
Change at Week 1170 ± NA
Change at Week 1210 ± NA
Change at Week 1250 ± NA
Change at Week 1290 ± NA
Change at Week 1330 ± NA
Change at Week 1370 ± NA
Change at Week 141-1.00 ± NA
Change at Week 145-1.00 ± NA
SecondaryMBQ for Female Participants of Childbearing Potential: Change From Baseline in the Pain Subscale Score Over Time

The MBQ is a validated measure for menorrhagia and used to assess impact on the menstrual bleed-related heaviness, pain, irregularity, and quality of life (QoL). The MBQ is a 20-item measure covering four aspects regarding heavy menstrual bleeding: heaviness (8 items), QoL (8 items), irregularity (3 item), and pain (1 item). The total score for pain subscale ranges from 0 to 3. Higher score indicates severe pain.

Time frame:
Baseline, Weeks 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 89, 93, 97, 101, 104, 109, 113, 121, 125, 129, 133 and 137
Reported as:
Mean · score on scale
MBQ for Female Participants of Childbearing Potential: Change From Baseline in the Pain Subscale Score Over Time
score on scaleEmicizumab
Baseline1.50 ± 0.71
Change at Week 5-1.00 ± NA
Change at Week 9-1.00 ± 1.41
Change at Week 13-1.00 ± 1.41
Change at Week 17-0.50 ± 0.71
Change at Week 21-0.50 ± 2.12
Change at Week 25-2.00 ± NA
Change at Week 29-1.00 ± 1.41
Change at Week 33-1.00 ± 1.41
Change at Week 37-0.50 ± 2.12
Change at Week 41-2.00 ± NA
Change at Week 45-1.00 ± 1.41
Change at Week 490 ± NA
Change at Week 530 ± NA
Change at Week 570 ± NA
Change at Week 61-2.00 ± NA
Change at Week 650 ± NA
Change at Week 69-1.00 ± 1.41
Change at Week 73-1.00 ± 1.41
Change at Week 77-2.00 ± NA
Change at Week 81-2.00 ± NA
Change at Week 89-1.00 ± NA
Change at Week 93-1.00 ± NA
Change at Week 97-2.00 ± NA
Change at Week 101-1.00 ± NA
Change at Week 104-1.00 ± NA
Change at Week 109-2.00 ± NA
Change at Week 113-1.00 ± NA
Change at Week 121-1.00 ± NA
Change at Week 125-1.00 ± NA
Change at Week 129-2.00 ± NA
Change at Week 133-1.00 ± NA
Change at Week 137-2.00 ± NA
SecondaryMenstruation Diary With the Pictorial Blood Assessment Chart (PBAC) for Female Participants of Childbearing Potential: PBAC Scores Over Time

The Menstruation Diary used a PBAC, which has shown good correlation with menstrual blood loss. The PBAC is a chart that records the occurrence and size of clots, and the number of episodes of heavy bleeding (flooding), as well as depicts the amount of blood loss during a cycle.The PBAC records pad and tampon use (as either light \[1 point\], medium \[5 points\], or heavy \[10 points\] flow), clots (small \[1 point\] or large \[5 points\]), and flooding episodes (1 point each) which can be recorded as many times as necessary any day of the month. The PBAC is scored from 0 (no bleeding) onwards, with a score of \>100 defining abnormal coagulation and heavy menstrual bleeding (corresponds to \>80ml of blood loss per menstrual cycle).

Time frame:
Baseline and monthly (on days of menstruation) until Study Completion (up to approximately 247 weeks)
Reported as:
Mean · score on scale
Menstruation Diary With the Pictorial Blood Assessment Chart (PBAC) for Female Participants of Childbearing Potential: PBAC Scores Over Time
score on scaleEmicizumab
Month 1141.67 ± 140.69
Month 2134.00 ± 47.57
Month 3126.33 ± 41.67
Month 471.00 ± 49.43
Month 5103.33 ± 107.74
Month 6127.00 ± 77.12
Month 7104.50 ± 2.12
Month 873.67 ± 53.93
Month 949.67 ± 27.68
Month 1058.00 ± 42.93
Month 1136.00 ± 23.90
Month 1271.00 ± 43.41
Month 1367.67 ± 42.85
Month 1477.00 ± 36.77
Month 1527.67 ± 35.73
Month 1698.00 ± 32.53
Month 17101.67 ± 36.25
Month 1897.00 ± 42.43
Month 1956.00 ± 79.20
Month 2052.50 ± 14.85
Month 2190.50 ± 20.51
Month 2257.00 ± 15.56
Month 23109.50 ± 62.93
Month 2459.50 ± 26.16
Month 25100.00 ± 32.53
Month 2672.50 ± 74.25
Month 274.50 ± 6.36
Month 2869.50 ± 64.35
Month 2960.00 ± 26.87
Month 3051.00 ± NA
Month 3193.50 ± 57.28
Month 3279.50 ± 0.71
Month 3316.50 ± 20.51
Month 3477.50 ± 53.03
Month 3674.50 ± 71.42
SecondaryNumber of Participants With at Least One Adverse Event by Severity, According to the World Health Organization (WHO) Toxicity Grading Scale

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. As per WHO toxicity grading, Grade 1= mild, 2= moderate, 3=severe, 4=life threatening.

Time frame:
From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event by Severity, According to the World Health Organization (WHO) Toxicity Grading Scale
ParticipantsEmicizumab
Grade-120
Grade-238
Grade-37
Grade-42
SecondaryNumber of Participants With Adverse Events Leading to Study Drug Discontinuation

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

Time frame:
From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Study Drug Discontinuation
ParticipantsEmicizumab
Number of Participants With Adverse Events Leading to Study Drug Discontinuation0
SecondaryNumber of Participants With at Least One Thromboembolic Event

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The following signs and symptoms were recognized as potential thromboembolism (i.e., dyspnea, chest pain, leg pain, or swelling; or if in the head, headache, numbness in the face, eye pain or swelling, or vision impairment).

Time frame:
From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Thromboembolic Event
ParticipantsEmicizumab
Number of Participants With at Least One Thromboembolic Event2
SecondaryNumber of Participants With at Least One Event of Thrombotic Microangiopathy

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. TMA is used to describe a group of disorders with clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys, gastrointestinal system, central nervous system, etc.

Time frame:
From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Event of Thrombotic Microangiopathy
ParticipantsEmicizumab
Number of Participants With at Least One Event of Thrombotic Microangiopathy0
SecondaryNumber of Participants With at Least One Injection-Site Reaction by Severity, According to the WHO Toxicity Grading Scale

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Injection-site reactions are defined as AEs related that occur within 24 hours after study drug administration and are judged to be related to the study drug injection. Local injection-site reactions included erythema, hematoma, rash, discomfort, pain, and pruritus and were mostly of mild and moderate intensity. As per WHO toxicity grading, Grade 1= mild, 2= moderate, 3=severe, 4=life threatening.

Time frame:
From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Injection-Site Reaction by Severity, According to the WHO Toxicity Grading Scale
ParticipantsEmicizumab
Grade-113
Grade-20
Grade-30
Grade-40
SecondaryNumber of Participants With at Least One Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Event

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

Time frame:
From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Event
ParticipantsEmicizumab
Number of Participants With at Least One Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Event0
SecondaryNumber of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4

An abnormal laboratory value was defined as a laboratory test result outside of the normal range for hematology or serum chemistry parameters. The WHO toxicity grading scale, which ranges from Grades 1 to 4 (least severe to most severe, respectively; Grade 0 is within normal range), was used for assessing the severity of laboratory abnormalities and adverse events (WHO 2003). Not every laboratory abnormality qualified as an adverse event; an abnormality was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment.

Time frame:
Up to approximately 274 weeks
Reported as:
Count of participants · Participants
Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4
ParticipantsEmicizumab
Calcium (Low): Grade 0 (Baseline) to Grade4 (PB)1
Glucose (High): Grade1 (Baseline) to Grade 3 (PB)2
Phosphorus (low):Grade 0 (Baseline) to Grade 3 (PB)2
Phosphorus (low): Grade0 (Baseline) to Grade 4(PB)1
Potassium(high):Grade0 (Baseline) to Grade 3(PB)2
Potassium(high): Grade0 (Baseline) toGrade4(PB)1
AST(high): Grade0 (Baseline to Grade 3(PB)2
SecondaryNumber of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs

The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. All of the adverse events reported here were assessed independently by the investigator as not related to treatment with emicizumab.

Time frame:
Up to approximately 274 weeks
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs
ParticipantsEmicizumab
Pyrexia4
Hypertension1
SecondaryChange From Baseline in Electrocardiogram (ECG) Parameters Over Time: QT, QTcB, QTcF, RR, PR, and QRS Intervals
Time frame:
Baseline, Weeks 5, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, SC/ED (up to approximately 274 weeks)
Reported as:
Mean · milliseconds
Change From Baseline in Electrocardiogram (ECG) Parameters Over Time: QT, QTcB, QTcF, RR, PR, and QRS Intervals
millisecondsEmicizumab
QT: Baseline387.6 ± 34.3
QT: Change at Week 5-2.7 ± 21.1
QT: Change at Week 250.8 ± 25.7
QT: Change at Week 494.3 ± 25.1
QT: Change at Week 61-2.8 ± 21.5
QT: Change at Week 73-2.2 ± 26.8
QT: Change at Week 85-1.0 ± 26.1
QT: Change at Week 973.2 ± 27.1
QT: Change at Week 1091.0 ± 29.3
QT: Change at Week 1211.9 ± 22.5
QT: Change at Week 1334.4 ± 22.4
QT: Change at Week 1456.4 ± 22.4
QT: Change at Week 1577.6 ± 20.2
QT: Change at Week 1693.9 ± 30.2
QT: Change at Week 18119.8 ± 9.4
QT: Change at SC/ED4.1 ± 25.7
PR: Baseline146.1 ± 25.6
PR: Change at Week 5-1.3 ± 11.4
PR: Change at Week 251.1 ± 11.6
PR: Change at Week 491.5 ± 17.3
PR: Change at Week 611.4 ± 12.1
PR: Change at Week 73-0.1 ± 13.0
PR: Change at Week 851.9 ± 15.6
PR: Change at Week 971.1 ± 19.7
PR: Change at Week 1095.4 ± 13.4
PR: Change at Week 1212.8 ± 15.3
PR: Change at Week 1334.1 ± 13.7
PR: Change at Week 1456.9 ± 11.5
PR: Change at Week 1577.2 ± 15.1
PR: Change at Week 1697.8 ± 12.9
PR: Change at Week 181-2.5 ± 7.0
PR: Change at SC/ED3.5 ± 10.9
QRS: Baseline89.4 ± 14.4
QRS: Change at Week 50.6 ± 10.6
QRS: Change at Week 251.5 ± 11.8
QRS: Change at Week 491.3 ± 12.7
QRS: Change at Week 610.5 ± 13.0
QRS: Change at Week 730.8 ± 13.8
QRS: Change at Week 850.9 ± 15.1
QRS: Change at Week 972.6 ± 14.7
QRS: Change at Week 1091.4 ± 13.7
QRS: Change at Week 1210.3 ± 15.0
QRS: Change at Week 1332.5 ± 12.9
QRS: Change at Week 1452.2 ± 11.0
QRS: Change at Week 1572.3 ± 12.9
QRS: Change at Week 1692.1 ± 13.2
QRS: Change at Week 1813.3 ± 29.1
QRS: Change at SC/ED4.1 ± 12.3
SecondaryChange From Baseline in Heart Rate Over Time, as Measured by ECG
Time frame:
Baseline, Weeks 5, 25, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169, 181, SC/ED (up to approximately 274 weeks)
Reported as:
Mean · beats per minutes
Change From Baseline in Heart Rate Over Time, as Measured by ECG
beats per minutesEmicizumab
Baseline70.2 ± 15.7
Change at Week 5-1.2 ± 9.9
Change at Week 25-2.5 ± 9.9
Change at Week 49-4.2 ± 11.7
Change at Week 61-2.2 ± 11.9
Change at Week 73-1.3 ± 12.5
Change at Week 85-1.4 ± 12.3
Change at Week 97-4.5 ± 12.3
Change at Week 109-1.7 ± 14.7
Change at Week 121-1.9 ± 13.0
Change at Week 133-3.9 ± 11.7
Change at Week 145-6.7 ± 12.3
Change at Week 157-8.1 ± 15.2
Change at Week 169-3.3 ± 13.3
Change at Week 181-8.8 ± 10.5
Change at SC/ED-3.9 ± 12.8
SecondaryPlasma Trough Concentration (Ctrough) of Emicizumab Over Time
Time frame:
Pre-dose at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, 169 and 181 (up to approximately 274 weeks)
Reported as:
Geometric mean · micrograms per millilitre (μg/mL)
Plasma Trough Concentration (Ctrough) of Emicizumab Over Time
micrograms per millilitre (μg/mL)Emicizumab 1.5 mg/kg QWEmicizumab 3 mg/kg Q2WEmicizumab 6 mg/kg Q4W
Week 1NA ± NANA ± NANA ± NA
Week 219.2 ± 20.820.9 ± 25.416.7 ± 32.7
Week 335.3 ± 24.937.7 ± 20.431.9 ± 30.6
Week 448.7 ± 24.449.1 ± 23.444.3 ± 34.1
Week 559.7 ± 20.460 ± 1856.8 ± 33.4
Week 958.9 ± 29.159 ± 22.250.1 ± 25.3
Week 1359.4 ± 32.655 ± 3144.9 ± 21.7
Week 1756.6 ± 22.253.2 ± 27.448.5 ± 26.2
Week 2156.6 ± 28.651.8 ± 31.746.6 ± 21.8
Week 2556.2 ± 30.851.2 ± 3345.2 ± 21
Week 2954.4 ± 32.751.2 ± 2845.1 ± 24.4
Week 3356 ± 33.751 ± 37.843.9 ± 25.5
Week 3756.9 ± 33.652.5 ± 3047 ± 26.2
Week 4152.3 ± 27.151.2 ± 46.138.2 ± 56.2
Week 4558.7 ± 37.749.4 ± 36.845.9 ± 27.1
Week 4955.8 ± 42.551.8 ± 35.647.3 ± 33.1
Week 6155.5 ± 47.951.6 ± 73.348.9 ± 28.4
Week 7353.6 ± 54.753.7 ± 41.848.1 ± 28.8
Week 8554.3 ± 88.347.5 ± 71.246.5 ± 24.4
Week 9747.8 ± 80.137.9 ± 15649.4 ± 21.3
Week 10953.9 ± 29.636.4 ± 23042.1 ± 31.9
Week 12145.1 ± 67.141.7 ± 86.142.3 ± 27
Week 13341.1 ± 11636.4 ± 10243.1 ± 26.2
Week 14542.6 ± 62.430.1 ± 21548.4 ± 27.5
Week 15757.3 ± 29.542.5 ± 54.542.9 ± 11.6
Week 16962.5 ± 55.752.5 ± 53.851.1 ± 12.9
Week 181—57.7 ± 34.8—
SecondaryNumber of Participants With Anti-Drug Antibodies Against Emicizumab at Baseline and Post-Baseline

Participants were considered to be ADA positive if they were ADA negative at baseline but develop an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response). The sum of all visits has been reported here.

Time frame:
Baseline, Weeks 5, 13, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 169, 181 and SC/ED (up to approximately 274 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies Against Emicizumab at Baseline and Post-Baseline
ParticipantsEmicizumab
Number of Participants With Anti-Drug Antibodies Against Emicizumab at Baseline and Post-Baseline2
SecondaryNumber of Participants Who Develop Anti-FVIII Inhibitors Over Time

Central laboratory measurement of anti-FVIII inhibitory antibodies (inhibitors) was performed using a Chromogenic Bethesda Assay (CBA). Participants who develop anti-FVIII inhibitors (titer ≥ 0.6 Bethesda units per milliliter \[BU/mL\]) following study drug administration were summarized.

Time frame:
Up to approximately 274 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Develop Anti-FVIII Inhibitors Over Time
ParticipantsEmicizumab
Number of Participants Who Develop Anti-FVIII Inhibitors Over Time2

Adverse events

Collected over From enrollment until final completion date cutoff (median [range, min-max] observation period: 156.21 [24.1 - 274.0] weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Emicizumab0/72 (0%)17/72 (23.6%)55/72 (76.4%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventEmicizumab
Abdominal painGastrointestinal disorders1/72
Mallory-Weiss syndromeGastrointestinal disorders1/72
COVID-19Infections and infestations1/72
DiverticulitisInfections and infestations1/72
ErysipelasInfections and infestations1/72
ConcussionInjury, poisoning and procedural complications1/72
ContusionInjury, poisoning and procedural complications1/72
Foreign body in gastrointestinal tractInjury, poisoning and procedural complications1/72
HyperglycaemiaMetabolism and nutrition disorders1/72
Renal colicRenal and urinary disorders1/72
Most frequent other events
Showing 10 of 18
Most frequent other events
EventEmicizumab
COVID-19Infections and infestations23/72
ArthralgiaMusculoskeletal and connective tissue disorders16/72
HeadacheNervous system disorders14/72
NasopharyngitisInfections and infestations14/72
Injection site reactionGeneral disorders13/72
Pain in extremityMusculoskeletal and connective tissue disorders9/72
FallInjury, poisoning and procedural complications9/72
Limb injuryInjury, poisoning and procedural complications6/72
Abdominal pain upperGastrointestinal disorders5/72
DiarrhoeaGastrointestinal disorders5/72

Baseline characteristics

The All Participants Population includes all participants who enrolled in the study.

Age, Continuous
Age, Continuous(Years)Emicizumab
Mean25.9 ± 17.0
Age, Customized
Age, Customized(Participants)Emicizumab
2 to <6 Years Old5
6 to <12 Years Old11
12 to <18 Years Old14
18 to <65 Years Old41
≥65 Years Old2
Sex: Female, Male
Sex: Female, Male(Participants)Emicizumab
Female3
Male70
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Emicizumab
Hispanic or Latino2
Not Hispanic or Latino61
Unknown or Not Reported10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Emicizumab
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American6
White62
More than one race0
Unknown or Not Reported2
Hemophilia A Severity
Hemophilia A Severity(Participants)Emicizumab
Mild21
Moderate52
Emicizumab Maintenance Dosing Regimen Chosen at Enrollment
Emicizumab Maintenance Dosing Regimen Chosen at Enrollment(Participants)Emicizumab
1.5 mg/kg Once Every Week (QW)25
3 mg/kg Once Every 2 Weeks (Q2W)39
6 mg/kg Once Every 4 Weeks (Q4W)8
Not Assigned (Not Treated)1
08

Study locations

22 sites
  • Childrens Hospital LA
    Los Angeles, California 90027, United States
  • Hemophilia of Georgia Center for Bleeding & Clotting Disorders
    Atlanta, Georgia 30308, United States
  • Indiana Hemophilia & Thrombosis center
    Indianapolis, Indiana 46260, United States
  • University of Michigan, C.S. Mott Children's Hospital
    Ann Arbor, Michigan 48109, United States
  • Washington Institute for Coagulation
    Seattle, Washington 98101, United States
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Kaye Edmonton Clinic
    Edmonton, Alberta T6G 1Z1, Canada
  • Eastern Health - General Hospital
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Hopital Cardio-vasculaire Louis Pradel
    Bron, 69677, France
  • CH de Bicetre
    Le Kremlin-Bicêtre, 94275, France
  • Groupe Hospitalier Necker Enfants Malades
    Paris, 75015, France
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
  • Klinikum der Universität München, Campus Innenstadt
    München, 80336, Germany
  • Amsterdam UMC Location AMC
    Amsterdam, 1105 AZ, Netherlands
  • Instytut Hematologii i Transfuzjologii
    Warsaw, 02-776, Poland
  • Charlotte Maxeke Johannesburg Hospital
    Johannesburg, 2193, South Africa
  • Hospital Universitario la Paz
    Madrid, 28046, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, 41013, Spain
  • Cardiff and Vale NHS Trust
    Cardiff, CF14 4XW, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Great Ormond street Hospital for Children NHS Foundation Trust
    London, WC1N 3HR, United Kingdom
09

References and documents

Publications

  • Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jimenez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27. PubMed 36716761 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Oct 2021, 20 months.

Results were first posted in Dec 2022, 1 year 1 month after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 20 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2019
First posted
Nov 12, 2019
StartActual
Feb 10, 2020
Primary completionActual
Oct 30, 2021
CompletionActual
Dec 19, 2025
Results first posted
Dec 15, 2022
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04158648
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 12, 2019
Start date
Feb 10, 2020
Primary completion
Oct 30, 2021
Completion
Dec 19, 2025
Results posted
Dec 15, 2022
Last update
Aug 27, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emicizumab

Start the discussion